Study Title: 
Sponsor: 
IND N umb er: 
Eudra CT N umb er: 
Clinical Trial s.gov 
Identifier: 
Indication: 
Prot ocol ID: 
Clinical Program 
Manager: 
Gilead Medical 
Monitor: 
Prot ocol Version/Date: (rJ GILEAU 
CLINICAL STUDY PROTO COL 
A Ph ase 2, Open -Label, Randomized Study to Evaluate the Efficacy 
and Safety of GS-5745 Comb ined with Nivo lumab versus Nivolumab 
Alone in Subjects with Unresectab le or RecmTent Gastric or 
Gastroesophageal Junct ion Adenocarc inoma 
Gilead Sciences , Inc. 
333 Lake side Drive 
Foster City, CA 94404 
116561 
2016 -001402 -41 
[STUDY_ID_REMOVED] 
Gastric Adenocarc inoma 
GS-US-296-2013 
Name: PD 
Telephone: PD 
Email : PU 
Name: PD 
Telephone: PD 
Fax: PD 
Cell: PD 
Email : PU 
Original: 30 Marc h 2016 
Ame ndment 1: 13 June 2016 
Ame ndment 2: 2 Augu st 2016 
Ame ndment 3: 16 June 2017 
CONFIDENTIALITY STAT EMEN T 
The info1mat ion contained in this docume nt, paiiicula rly unpublis hed data, is the prope 1iy or 
unde r control of Gilead Sciences, Inc., and is prov ided to you in confide nce as an investigato r, 
potential investigator , or consu ltant, for review by you, yow- staff, and an applicable Institutio nal 
Review Board or Indepe ndent Ethics Comm ittee. The infonnation is only to be used by you in 
connectio n with authorized clinical studies of the investigational dmg descr ibed in the protocol. 
You will not disclo se any of the infonnation to others without written author izatio n from 
Gilead Sciences, Inc., except to the extent neces saiy to obtain infonned consent from those 
persons to whom the dmg may be admin istered. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 2 16June 2017TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................
........................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 14
1. INTRODUCTION .............................................................................................................................................. 17
1.1. Background ............................................................................................................................................ 17
1.1.1. Gastric Adenocarcinoma ...................................................................................................... 18
1.1.2. MMP9 Expression in Oncology ........................................................................................... 20
1.1.3. General Information ............................................................................................................. 20
1.1.4. Preclinical Pharma cology and Toxicology ........................................................................... 21
1.1.5. Clinical Trials of Andecaliximab ......................................................................................... 27
1.1.6. Information about Nivolumab .............................................................................................. 28
1.2. Rationale for this Study .......................................................................................................................... 28
1.3. Risk/Benefit Assessment for the Study .................................................................................................. 29
1.4. Com pliance ............................................................................................................................................ 30
2. OBJECTIVES ................................................................................................
..................................................... 31
3. STUDY DESIGN ................................................................................................................................................ 32
3.1. Endpoints ............................................................................................................................................... 32
3.2. Study Design .......................................................................................................................................... 32
3.3. Study Treatments ................................................................................................................................... 33
3.4. Duration of Treatment ............................................................................................................................ 33
3.5. Discontinuation Criteria from Treatment ............................................................................................... 33
3.5.1. Discontinuation Criteria for Nivolumab ............................................................................... 34
3.6. Prem ature Discontinuation from Study Treatment ................................................................................. 34
3.7. Discontinuation Criteria from Study ...................................................................................................... 35
3.8. Long -Term  Follow -Up for Overall Survival .......................................................................................... 35
3.9. Source Data ..............................................................................................................................
.............. 35
3.10. Biomarker Testing ..............................................................................................................................
....36
3.10.1. Biomarker Samples to Address the Study Objectives: ......................................................... 36
3.10.2. Biologic Samples for Optional Future Research .................................................................. 39
4. SUBJECT POPULATION .................................................................................................................................. 40
4.1. Number of Subjects and Subject Selection ...............................................................
............................. 40
4.2. Inclusion Criteria .................................................................................................................................... 40
4.3. Exclusion Criteria ................................................................................................................................... 41
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 44
5.1. Randomization ....................................................................................................................................... 44
5.2. Description and Handling of Study Treatments ..................................................................................... 44
5.2.1. Form ulation .......................................................................................................................... 44
5.2.2. Packaging and Labeling ....................................................................................................... 44
5.2.3. Storage and Handling ........................................................................................................... 45
5.3. Dosage and Administration of Study Drug ............................................................................................ 45
5.3.1. Dose Adjustments ...............................................................
................................................. 45
5.4. Prior and Concomitant Medications ....................................................................................................... 46
CCI-
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 3 16June 20175.4.1. Acceptable Concomitant Medications .................................................................................. 46
5.4.2. Prohibited Concomitant Medication s................................................................................... 46
5.5. Accountability for Study Drug ............................................................................................................... 47
5.5.1. Study Drug Return or Disposal ............................................................................................ 48
6. STUDY PROCEDURES .................................................................................................................................... 49
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 49
6.2. Study Procedure Descriptions ................................................................................................................ 49
6.2.1. Informed Consent ................................................................................................................. 49
6.2.2. Re-Screening Criteria ........................................................................................................... 50
6.2.3. Medical & Medication History ............................................................................................. 50
6.2.4. Physical Examination ........................................................................................................... 50
6.2.5. Vital Signs & Weight ........................................................................................................... 50
6.2.6. Electrocardiogram Assessment ...............................................................
............................. 51
6.2.7. Performance Status ............................................................................................................... 51
6.2.8. Laboratory Assessments ....................................................................................................... 51
6.2.9. Disease and Response Assessment ....................................................................................... 54
6.2.10. Study Drug Administration .................................................................................................. 57
6.2.11. Adverse Events ..................................................................................................................... 58
6.3. Assessments for Premature Discontinuation from Study ....................................................................... 58
6.4. Criteria for Discontinuation of Study Treatment ...............................................................
..................... 58
6.5. End of Treatment .................................................................................................................................... 58
6.6. End of Study ........................................................................................................................................... 58
6.7. 30-Day Safety Follow -Up................................ ...................................................................................... 59
6.8. 5-Month Safety Follow -Up.................................................................................................................... 59
6.9. Long -Term  Follow -Up........................................................................................................................... 59
6.10. Unscheduled visits ..............................................................................................................................
...59
6.11. Protocol Deviations ................................................................................................................................ 59
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 60
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 60
7.1.1. Adverse Events ..................................................................................................................... 60
7.1.2. Serious Adverse Events ........................................................................................................ 60
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessment
s as 
Adverse Events or Serious Adverse Events ......................................................................... 61
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................
.62
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 62
7.2.2. Assessment of Severity ........................................................................................................ 62
7.3. Investigator Requirements and Instructions for Repo rting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 63
7.3.1. Adverse Events ..................................................................................................................... 63
7.3.2. Serious Adverse Events ........................................................................................................ 63
7.4. Gilead Reporting Requirements ...............................................................
.............................................. 64
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events .......................................................................................................................... 64
7.6. Toxicity Management ............................................................................................................................ 65
7.7. Special Situations Reports ...................................................................................................................... 65
7.7.1. Definitions of Special Situations .......................................................................................... 65
7.7.2. Instructions for Reporting Special Situations ....................................................................... 66
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 68
8.1. Analysis Objectives and Endpoints ........................................................................................................ 68
8.1.1. Analysis Objectives .............................................................................................................. 68
8.1.2. Primary Endpoint ................................................................................................................. 68
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 4 16June 20178.1.3. Secondary Endpoint ............................................................................................................. 68
8.1.4. Other Endpoints of Interest .................................................................................................. 69
8.2. Analysis Conventions ............................................................................................................................. 69
8.2.1. Analysis Sets ........................................................................................................................ 69
8.3. Data Handling Conventions ................................................................................................................... 70
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 71
8.5. Efficacy Analysis ..............................................................................................................................
.....71
8.5.1. Primary Analysis .................................................................................................................. 71
8.5.2. Second ary Analyses ............................................................................................................. 71
8.6. Safety Analysis ....................................................................................................................................... 71
8.6.1. Extent of Exposure ............................................................................................................... 71
8.6.2. Adverse Events ..................................................................................................................... 72
8.6.3. Laboratory Evaluations ........................................................................................................ 72
8.6.4. Other Safety Evaluations ...............................................................
....................................... 72
8.7. Pharm acokinetic Analysis ...................................................................................................................... 72
8.8. Biomarker Analysis ................................................................
................................................................ 73
8.9. Interim Safety Analys is.......................................................................................................................... 73
8.10. Sample Size ............................................................................................................................................ 73
8.11. Data Monitoring Committee ...............................................................
................................................... 73
9. RESPONSIBILITIES .......................................................................................................................................... 74
9.1. Investigator Responsibilities .................................................................................................................. 74
9.1.1. Good Clinical Practice .......................................................................................................... 74
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ........................................................................................................... 74
9.1.3. Informed Consent ................................................................................................................. 74
9.1.4. Confidentiality ...............................................................
....................................................... 75
9.1.5. Study Files and Retention of Records .................................................................................. 75
9.1.6. Case Report Forms ............................................................................................................... 76
9.1.7. Study Drug Accou ntability and Return ................................................................................ 77
9.1.8. Inspections ............................................................................................................................ 77
9.1.9. Protocol Compliance ............................................................................................................ 77
9.2. Sponsor Responsibilities ........................................................................................................................ 78
9.2.1. Protocol Modifications ......................................................................................................... 78
9.2.2. Study Report and Publications ............................................................................................. 78
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 78
9.3.1. Payment Reporting ............................................................................................................... 78
9.3.2. Access to Information for Monitoring .................................................................................. 79
9.3.3. Access to Information for Auditing or Inspections .............................................................. 79
9.3.4. Study Discontinuation .......................................................................................................... 79
10. REFERENCES ................................................................................................................................................... 80
11. APPENDICES .................................................................................................................................................... 85
Appendix 1. Investigator Signature Page .................................................................................................... 86
Appendix 2. Study Procedures Table .......................................................................................................... 87
Appendix 3. ECOG Performance Status ..................................................................................................... 91
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 92
Appendix 5. Revised RECIST Guideline (version 1.1) .............................................................................. 95
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 5 16June 2017LIST OF IN -TEXT TABLES
Table 3-1. Biomarker Objectives and Testing ......................................................................................... 38
Table 6-1. Analytes .................................................................................................................................. 52
Table 6-2. Imaging and Treatment after First Radiologic Evidence of Progressive Disease ................... 56
LIST OF IN -TEXT FIGURES
Figure 1-1. Examples of MMP9 Expression in Gastric Adenocarcinoma (IHC) ...................................... 20
Figure 1-2. Summary of Pro -Tum origenic Activities of MMP9 ............................................................... 21
Figure 1
-3. Changes in Tumor -Associated Fibrillar Collagen .................................................................. 22
Figure 1
-4. Effect of MMP9 Inhibition in the HCT -116 Orthotopic Model of CRC ................................ 23
Figure 1-5. Hypothesis for Andecaliximab and Nivolumab ...................................................................... 24
Figure 1-6. Inhibition of MMP9 in Orthotopic HC11 -NeuT Model of Breast Cancer .............................. 24
Figure 1
-7. Changes in Tumor -Associated Fibrillar Collagen .................................................................. 25
Figure 1-8. Transcriptome and Pathway Analysis of the HC11 -NeuT Model .......................................... 26
Andecaliximab (fo1medy GS-5745 ) 
Protoco l GS-US-296 -2013 Final 
Amendment3 Gilead Sciences , Inc. 
Study Title: 
IND Number: 
Eudra CT N umber: 
Clinical Trial s.gov 
Identifier: 
Study Center s 
Planned: 
Objecti ves: 
CONFIDENTIAL PROTO COL SYNOP SIS 
Gilead Science s, Inc. 
333 Lake side Drive 
Foster City, CA 94404 
A Phase 2, Open-Labe l, Ran domized Study to Evaluate the Efficacy and 
Safety of GS-5745 Combined with Nivol umab versus Ni volumab Alone 
in Subjects with Um esectable or RecmTent Gastric or Gastroesop hageal 
Junction Adenocarc inoma 
116561 
2016 -001402-41 
[STUDY_ID_REMOVED] 
Approximately 50 centers in Aust rnlia , Nort h America , and Em-ope 
The prima1 y objective of this study is: 
• To evaluate and compare the efficacy of andecaliximab (fo1me rly 
GS-57 45) in combinatio n with nivolumab versus nivolumab alone in 
subjects with recmTent gastric or gastroesop hagea l junction (GEJ) 
adenocarc inoma 
The secondaiy objectives of this study are: 
• To chai·acterize and compai·e safety and tolerab ility of 
andeca liximab in combin ation with nivolumab versus nivolumab 
alone in subjects with recunent gastric or GEJ adenocarcinoma 
• To chai·acter ize the ph aimacok inetics (PK) of andeca liximab in 
combination w ith nivolumab 
The explorato 1 y objectives of this study are: 
I 
I I I 
I 
Page6 16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 7 16June 2017Study Design: This is a Phase 2, open -label, randomized study  comparing 
andecaliximab in combination with nivolumab in recurrent gastric 
adenocarcinoma versus nivolumab alone. Approximately  120subjects 
will be randomized to either Treatment Arm A: andecaliximab + 
nivolumab or Treatment Arm B: nivol umab alone . 
To evaluate combination drug safet y, an independent Data Monitoring 
Committee (DMC) will be charged with overseeing the stud y safet y. 
After the first 20 subjects are treated for 12 weeks, the DMC will review 
all safet y data to evaluate for any unexpected toxicities. I f the DMC 
recommends that the combination demonstrate sacceptable tolerability , 
enrollment and randomization will proceed with conti nued safet y 
oversight from the DMC. Thereafter, review of safety data will be 
performed at regular intervals as described in the DMC charter.
Randomized study :
Treatment Groups:
Arm A: andecaliximab + nivolumab
Arm B: nivolumab
Randomization and Stratification:
1:1 allocation to andecaliximab + nivolumab versus nivolumab alone 
through an interactive web response s ystem (IWRS)
Fixed -block centralized randomization stratified by : 
PD-L1 positive versus PD-L1 negative
Number of 
Subjects Planned:Approximately  120 subjects 
Screening I 
I Arm A 
: N=60 
Arm B 
I N=60 
I 
I 
Strat ifi~ation and 
Random ization GS-5745 + Nivolumab 
u to 2 ears 
Nivolumab 
u to 2 ears Long-Term Follow-Up > 
L_.::Lo~n~g~ -.:.: lie::r.:.:m.:...:...;Fo:..:l:..:lo-'-w_ -_U.:...p __ > 
Disease 
progress ion or 
study stopped 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 8 16June 2017Target 
Population:Subjects who are ≥18 y ears or older with a histologically  confirmed 
inoperable locally  advanced or metastatic adenocarcinoma of the 
stomach or the gastroesophageal j unction ( GEJ)and who have 
progressed on at least 1prior systemic therapy  or line of treatment for 
unresectable/metastatic disease
Duration of 
Treatment:Treatment will be given every  2 weeks and will continue until disease 
progression, unacceptable toxicity , or withdrawal of consent to a 
maximum of 2 y ears duration
Eligibility  
Criteria:Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible 
for participation in this study :
1)Age ≥18 years 
2)Histologicall y confirmed inoperable locally advanced or metastatic 
adenocar cinoma of the stomach or GEJ which have progressed on at 
least 
1prior systemic therapy  or line of treatment for 
unresectable/metastatic disease
3)Eastern Cooperative Oncology  Group (ECOG) ≤ 1
4)Measurable disease according to RECI ST v1.1
5)Tumor sites that can be accessed for repeat biopsies 
6)Archival tumor tissue , preferably obtained from the most recent 
available biops y; there must be adequate tissue for a PD-L1 
stratification test , as assessed by  central pathologist
7)All toxicities attribu ted to prior anti -cancer therapy  other than 
alopecia and fatigue must have resolved to G rade 1 (NCI CTCAE 
version 4) or baseline
8)Subjects not receiving anticoagulant medication must have an 
international normalized ratio (INR) ≤1.5 and activated partial 
thromboplastin (aPTT) ≤1.5 x upper limit of norm al (ULN) prior to 
randomization. The use of full -dose oral or parenteral anticoagulants 
is permitted as long as the INR or aPTT is within therapeutic limits 
(according to the medical standard in the instituti on) and the subject 
has been on a stable dose of anticoagulants for at least 1 week at the 
time of randomization
9)Adequate hematologic function
a)neutrophils ≥ 1.5 x 109/L
b)platelets ≥100 x 109/L
c)hemoglobin ≥9 g/dL
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 9 16June 201710) Adequate hepatic function
a)Direct or total b ilirubin ≤1.5 x ULN
b)ALT and AST ≤ 2.5 x ULN
11) Creatinine clearance (CL cr) ≥ 60 mL /min, estimated based on the 
Cockroft -Gault formula or measured based on 24 -hour urine 
collection or other reliable method
12) For female subjects of childbearing potential, willingness to use a 
protocol -recommended method of contraception from the screening 
visit throughout the study treatment period, for 90 days following 
the last dose of andecaliximab and at least 5 months after the last 
dose of nivolumab, unless the subjec t chooses continuous 
heterosexual abstinence as a lifesty le-choice (seeAppendix 4for 
more information)
13)For male subjects of reproductive potential having intercourse with 
females of childbearing potential, willingness to use a protocol 
recommended method of contraception and to refrain from sperm 
donation from the start of study  drug, throughout the study  treatment 
period, andfor 90 day s after adm inistration of the last dose of 
andecaliximab ornivolumab (see Appendix 4for more information)
14)Breastfeedin g females must agree to discontinue nursing before 
study  drug administration
15)In the judgment of the investigator, participation in the protocol 
offers an acceptable benefit -to-risk ratio when considering current 
disease status, medical condition, and the potential benefits and risks 
of alternative treatments for the subject’s cancer
16)Willingness to comply  with scheduled visits, drug administration 
plan, imaging studies, laboratory  tests, other study  procedures, and 
study  restrictions
17)Evidence of a signed informed consent prior to implementation of 
any protocol specific procedure
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are n ot to be 
enrolled in this study :
1)Subjects that have received only  neoadjuvant or adjuvant therapy  for 
gastric adenocarcinoma
2)Radiotherap y wit hin 28 day s of randomization; s
ubjects given 
palliative radiotherap y to peripheral sites (eg, bone metastasis) may  
enter the stud y before 28 days have elapsed provided the radiated 
sites do not contain lesions which may  be used to evaluate response, 
and must have recovered from an y acute, reversible effects
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 10 16June 20173) Uncontrolled intercurrent illness including, but not limited to, active 
uncontrolled infection, active gastrointestinal bleeding, uncontrolled 
cardiac arrh ythmia, or psy chiatric illness/social situation that would 
limit compliance with study  requirements as judged by thetreating 
physician
4)History  of a concurrent or second malignancy  except for adequatel y 
treated local basal cell or squamous cell carcinoma of the skin; 
cervical carcinoma in situ; superficial bladder cancer; as ymptomatic 
prostate cancer without known metastatic disease, with no 
requirement for therap y or requiring onl y hormonal therap y, and 
with normal prostate -specific antigen for ≥ 1 y ear prio r to 
randomization; adequately  treated Stage 1 or 2 cancer currentl y in 
complete remission; or any  other cancer that has been in complete 
remission for 
≥ 5 y ears
5)Major surgery , defined as any  surgical procedure that involves 
general anesthesia and a signif icant incision (ie, larger than what is 
required for placement of central venous access, percutaneous 
feeding tube, or biops y), within 28 days of first dose of study drug
6)Known positive status for human immunodeficiency  virus (HIV)
7) Known acute or chronic-a ctive infection with hepatitis B virus 
(HBV) or hepatitis C virus (HCV)
8)Chronic daily  treatment with oral corticosteroids 
(dose of > 10 mg/day prednisone equivalent) or other 
immunosuppressive medications within 14 day s of randomization. 
Inhaled steroids a nd short co urses of oral steroids for anti- emesis or 
as an appetite stimulant are allowed
9)Known or suspected central nervous s ystem 
metastases
10)Known alcohol or drug abuse or an y other medical or psychiatric 
condition which contraindicates participation in the study
11)Documented my ocardial infarction or unstable/uncontrolled cardiac 
disease (ie, unstable angina, congestive heart failure [New York 
Heart Association > Class II ]) within 6 months of randomization
12)Serious sy stemic fungal, bacterial, viral, or other infection that is not 
controlled or requires intravenous antibiotics
13)Pregnant or breastfeeding women (pregnancy  needs to be excluded 
by testing of beta-human chorionic gonadotropin [β-hCG])
14)Experimental medical treatment within 28 day s prior to randomizat ion
15)Known hypersensitivity to andecaliximab or nivolumab or 
excipients or to Chinese hamster ovary  cell products or to 
recombinant human or humanized antibodies
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 11 16June 201716)Prior treatment with anti -CTL A-4 agents (ipilimumab), a nti-PD-1 or 
anti-PD-L1 agents (pem broliz umab, nivolumab), anti -PD-L2 agents, 
anti-MMP agents, or other immunomodulatory  therapies
17)Previous severe h ypersensitivity  reaction to treatment with another 
monoclonal antibody  therapy
18)Subject is expected to require an y other form of systemic or 
localized antine oplastic therap y while on stud y
19)Prior therapy  with anti -tumor vaccines or other immune -modulatory
antitumor agents
20)Current or history  of pneumonitis or interstitial lung disease
21)Active known or suspected autoimmune disease. Subjects with 
vitiligo, ty pe I diabetes mellitus, residual hy pothy roidism requiring 
hormone replacement, or conditions not expected to recur in the 
absence of an external trigger are permitted to enroll
22)History  of bone marrow, stem cell, or allogen eic organ 
transplantation
Study  Procedures/
Frequency :Screening will commence with obtaining the subject’s signed informed 
consent and will occur up to 28 day s prior to randomization on Day 1.
Screening procedures will include the following: medical history  
review, ph ysical exam, vital signs, 12 -
lead ECG, ECOG performance 
status, prior/concomitant medication review, blood collection for 
pregnancy  test (females), chemistry , hematology ,and coagulation, 
adverse event (AE) assessment, archival or recent biopsy  FFPE tissue 
block collection ,and computed tomograph y (CT) or magnetic resonance 
imaging ( MRI ). Baseline tumor lesions will be measured an d 
characterized prior to randomization to assess the subject ’sdisease 
status prior to beginning treatment. Archival tumor tissue adequate for 
PD-L1 immunohistochemical stratification test is required at screening.
Treatment:
Treatment will occur every  2 weeks
.  Subjects who meet eligibility  will 
undergo CT 
scans or MRI every  8 weeks. Starting on Day  1, subjects
randomized to Arm A : andecaliximab + nivolumab will receive 
andecaliximab viaintravenous 
infusion (IV) over 30 minutes.  
Nivolumab will be administered via IVover 60 minutes after 
andecaliximab . Subjects randomized to Arm B : nivolumab only will 
receive nivolumab via IVover 60 minutes.
Treatment will continue every  2 weeks in the absence of disease 
progression or toxicity  warranti ng disconti nuation of therap y, for up to 
2years. Tumor response may  be assessed prior to the speci fied every  
8weeks ,if clinically  indicated .
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 12 16June 2017Test Therapy, Dose, 
and Mode of 
Administration:Arm A: 800 mg andecaliximab viaIV infusion over approximately  
30minutes in advance of nivolumab 3 mg/kg via IV infusion over 
approximately  60minutes on Day  1 and every  2 weeks thereafter. 
Arm B: nivolumab 3 mg/kg via IV infusion over approximately  
60minutes on Day  1 and every  2 weeks thereafter.
Criteria for 
Evaluation:All subjects who meet eligibility  criteria ,have signed a consent form ,
and have begun tre atment, will be evaluated for response.
Safety : Safety  will be evaluated by  assessment of clinical laboratory  tests, 
physical examination, 12 -lead ECG, vital sign measurements, and b y the 
incidence of AEs.  
Efficacy : Objective response rate (ORR) will be determined from the subjec ts’ 
best response during treatment.
Progression free survival (PFS) will be defined as the interval from 
thedate of randomization to the earlier of the first documentation of 
definitive disease progression or death from an y cause.
Duration of response (DOR) will be defined as the interval from the 
date the first response (CR or PR) is achieved to the earlier of the 
first documentation of definitive disease progression or death from 
any cause .
Overall survival (OS) will be defin ed as the interval from date of 
randomization to death from any  cause.
Pharmacokinetics: Blood samples to measure andecaliximab will be collected at the 
time points specified in the protocol.
Blood samples to measure anti- andecaliximab antibodies will also be 
collected at the time points specified in the protocol.
Statistical Methods:
Analy sis 
Methods :Appropriate anal yses sets will be defined.
In general, categorical and ordinal data will be summarized by  count and 
percent of subjects. Continuous data will be summarized by  descriptive 
summary  statistics (mean, standard deviation, minimum, quartiles, 
median and maximum ).
For the anal ysis of ORR, a Cochran -Mantel -Haenszel (CMH) 
Chi-square test on odds ratio will be performed to compare the 
2treatment groups.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 13 16June 2017The Kaplan -Meier (KM) method and stratified log -rank test will be used 
to compare the 2 treatment groups for time-to-event endpoints (ie, OS 
and PFS ). A Cox proportional hazard model will be used to estimate the 
hazard ratio and corresponding 95 %confidence interval (CI). DOR will 
be anal yzed using the KM method.
Interim Anal ysis: After approximately  20 subjects are treated for 12 weeks, an 
independent DMC will review safet y data on these subjects and 
recommend to Gilead whether the treatment has demonstrated 
acceptable tolerability . Thereafter, review of safety  data will be 
performed at regular intervals as described in the DMC charter.
Sample Size: Assuming the ORR for 
subjects treated with nivolumab alone is 25%, 
120subjects in total are need ed to detect an improvement of 20% in 
ORR for 
subjects treated with andecaliximab and nivolumab with
approximately  83% power at one -sided significance level of 10% using 
a CMH test with anassumption of common odds ratio for all strata
.The 
assumption of nivolumab ORR is based on the upper bound of the 
95% confidence interval of the estimated ORR in CheckMate -032 Study
{Le 2016 }.
This study  will be conducted in accordance with the guidelines of Good Clinical Practices
(GCP s) including archiving of essential documents.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 14 16June 2017GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
β-hCG beta-human chorionic gonadotropin
λz terminal elimination rate constant; estimated by lin ear regression of the terminal 
elimination phase of the log serum/plasma/PBMC concentration versus time curve of the 
drug
5-FU 5-fluorouracil
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC last area under the plasma/serum/PBMC concentration versus time curve from time zero to the 
last quantifiable concentration
AUC tau area under the plasma/serum/PBMC concentration versus time curve over the dosing 
interval
BSA body surface area
Cmax maximum observed concentration of drug
CFR Code of Federal Regulations
CI confidence interval
Clast last observed quantifiable serum/plasma/PBMC concentration of the drug
CL cr creatinine clearance
Cmax maximum observed serum/plasma/PBMC concentration of drug
CR complete response
CRO contract research organization
CT computed tomography
Ctau observed drug concentration at the end of the dosing interval
CTCAE Common Terminology Criteria for Adverse Events
DCR disease control rate
DMC data monitoring committee
DNA deoxyribonucleic acid
DOR duration of response
DSPH Drug Safety and Public Health
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic Case Report Form
EOS end of study
EOT end of treatment
eSAE electronic serious adverse event
EU European Union
FDA Food and Drug Administration
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 15 16June 2017GCP good clinical practice
GEJ gastroesophageal junction
HBV hepatitis B virus
HCV hepatitis C virus
HER2 human epidermal growth factor receptor 2
HIV human immunodeficiency virus
HLT high-level term
HR hazard ratio
IB investigator’s brochure
IC50 concentration necessary to achieve 50% inhibition of target
ICH International Conference on Harmonisation
IHC immunohistochemistry
IMP investigational medicinal product
INR international normalized ratio
IRB/IEC institutional review board or independent ethics committee
ISH in situ hybridization
ITT intent -to-treat
IUD intrauterine device
IWRS interactive web response system
KM Kaplan -Meier
LV leucovorin
LTFU long- term follow -up
MMP matrix metalloproteinases
MRI magnetic resonance imaging
MSS musculoskeletal syndrome
ORR objective response rate
OS overall survival
PD progressive disease
PD-1 programmed death -1
PFS progression -free survival
PK pharmacokinetic
PR partial response
PRO patient -reported outcomes
RECIST Response Evaluation Criteria In Solid Tumor s
PT preferred term
RNA ribonucleic acid
SADR serious adverse drug reactions
SAE serious adverse event
SD stable disease
SOC system organ class
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 16 16June 2017SOP standard operating p rocedure
SUSAR suspected u nexpected s erious adverse reactions
t½ estimate of the terminal elimination half -life of the drug in serum/plasma/PBMC, 
calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz)
TIMPs tissue inhibitors of metalloproteinases
Tlast time (observed time point) of C last
TTR time to response
ULN upper limit of normal
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 17 16June 20171. INTRODUCTION
1.1. Background
Matrix metalloproteinases (MMP) comprise a family  of at least 23 Zn2+-dependent proteases 
which are involved in the degradation and remodeli ng of the extracellular matrix and basement 
membranes in and activation or degradation of growth factors, cy tokines and chemokines in 
many  normal as well as pathologic biological processes. They  are t ypicall y grouped based on 
their structure or their primary  substrates and include the gelatinases, collagenases, stromel ysins, 
matrily sins, an elastase, and membrane- type M MP, a group of cell surface tethered proteases
{Hu 2007, Mott 2004}. The gelatinases comprise MMP2 and MMP9, sometimes referred to as 
type IV collagenases, which are named for their ability  to degrade t ype IV or basement 
membrane collagen and gelatin, {Chen 2002, Kridel 2001 }.The contrasting roles of MMP9 and 
MMP2 have been revealed in a variet y of st udies which support a more ubiquitous expression 
pattern and associated role for MMP2 in normal tissue homeostasis, as compared to disease -
induced and pathology -associated expression and activity  of MMP9 {Agrawal 2006, Castaneda 
2005, Dubois 1999 , Garg 2009, Hu 2007, Itoh 2002 , Li 2009, Mi yazaki 2011 , Naito 2005, 
Santana 2006}. Various substrates have been identified for MMP9, and the active enz ymecan 
release cy tokines, growth factors, and bioactive fragments which in turn modu late inflammation, 
neovascularization ,tumorigenesis and matrix remodeling
{Hijova 2005}. MMP9 is an inducible 
MMP that is secreted as a zy mogen and activated in a “cy steine switch” mechanism by  the 
cleavage of the peptidoglycan binding domain
{Van Wart 1990}. While activation of MMP9 
appears to be carried out by  other MMPs, the protease’s activity  is also regulated by  the binding 
of tissue inhibitors of 
metalloproteinases (TIMPs), primarily  by TIMP1 {Imai 1995, Olson 1997, 
Vempati 2007 }. Elevated MMP9 expression in diseased tissue and plasma is associated with 
several human diseas
es. The health and largel y normal development of the MMP9 knockout 
mouse has enabled evaluation in a variet y of disease models, and these data support a significant 
role for MMP9 in a variety  of inflammatory , fibrotic , and oncologic processes {Dubois 1999 , Hu 
2007, Itoh 2002, Itoh 1999 , Opdenakker 2003 }.
The disease -
associated induction and functions of MMP9 render it an attractive therapeutic 
target.   In oncology , MMP9 can contribute to tumor growth through a variety  of mechanisms, 
including remodeling of the microenvironment, promotion of pro -tumorigenic and 
pro-angiogenic signaling pathway s, and blunting of anti- tumor immune responses.
Checkpo
int inhibitors, including therapeutic antibodies targeting programmed death -1 (PD -1) 
receptor such as nivolumab, have shown dramatic and sustained clinical benefit in melanoma, 
renal cell carcinoma , and subsets of other diverse solid tumors. These findings highlight the 
importance of immunomodulation in tumorigenesis. However, the response rate to these 
inhibitors remains limited in some of tumors such as gastric adenocarcinoma {Antonia 2015 }. 
Factors contributing to limitations in res ponse could include access of T cells to tumor cells due 
to the collagenous tumor desmoplastic reaction and tumor angiogenesis, in addition to repression 
of anti -tumor T -cell responses in the local tumor microenvironment resulting from the increased 
presence and activity  of myeloid suppressor cells ( MSC )and their associated cy tokines, 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 18 16June 2017chemokines, and growth factors. The combination of andecaliximab with nivolumab offers an 
opportunity  to broaden and deepen responses in gastric adenocarcinoma . Treatment with 
andecaliximab may 
result in productive remodeling of the tumor microenvironment to enable 
both T -cell and drug access, and the inhibition of both MSC recruitment and activation by 
andecaliximab may further inhibit tumor growth and promote anti- tumor immunity  in 
combination with nivolumab. 
1.1.1. Gastric Adenocarcinoma
Adenocarcinoma of the stomach is the most common gastrointestinal cancer in the world and the 
third leading cause of cancer death worldwide {Ferlay  2013 }. Approximatel y 22,220 patients are 
diagnosed annuall y in the United States, of whom 10,990 are expected to die. While the 
incidence of distal gas tric adenocarcinoma has recently declined in the United States, gastric 
adenocarcinoma remains quite frequent in certain minority  populat ions and it is still the 
second most common cause of cancer death worldwide. In addition, adenocarcinoma of the 
gastroe sophageal junction (GEJ )is one of the most rapidly  increasing solid tumors in the 
UnitedStates and Western Europe.
Most patients with 
gastric adenocarcinoma in the United States are s ymptomatic and already  
have advanced incurable disease at the time of p resentation. At diagnosis, approximately  
50percent have disease that extends bey ond loco regional confines, and only  one-half of those 
who appear to have locoregional tumor involvement can undergo a potentially  curative resection. 
Surgicall y curable earl y gastric adenocarcinoma s are usuall y asymptomatic and only  infrequentl y 
detected outside the realm of a screening program. Screening is not widely performed, except in 
countries which have a very  high incidence, such as Japan, Venezuela, and Chile. The common 
presenting s ymptoms and diagnostic approaches to gastric adenocarcinoma include weight loss 
(usually  results from insufficient caloric intake rather than increased catabolism) and may  be 
attributable to anorexia, nausea, abdominal pain, earl y satiet y, and/or d ysphagia. Abdominal pain 
is often present which tends to be epigastric, vague, and mild early in the disease but more severe 
and constant as the disease progresses. Dy sphagia is a common presenting sy mptom in patients 
with cancers arising in the pro ximal stomach or at the esophagogastric junction. Patients may  
also present with nausea or earl y satiet y from the tumor mass or in cases of an aggressive form of 
diffuse -type gastric adenocarcinoma called linitis plastica, from poor distensibility  of the 
stomach. They  may  also present with a gastric outlet obstruction from an advanced distal tumor.
Gastric and esophageal adenocarcinomas are chemotherapy  sensitive diseases, with several 
active drug therap y classes, including platinum, fluoropyrimidines, topo isomerases inhibitors, 
taxanes, and anthracy clines. Despite significant differences in epidemiology and molecular 
characteristics, cy totoxic chemotherap y combinations have not demonstrated significant 
differences in efficacy  across gastric adenocarcinoma. {Chau 2009}.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 19 16June 2017Chemotherap y clearl y provides a survival advantage over best supportive care in both first -line
{Glimelius 1997 , Murad 1993 , Pyrhonen 1995, Scheithauer 1995 }and second -line {Kang 2012, 
Thuss- Patience 2009} settings. A meta -analysis of first -line chemotherap y versus best supportive 
case studies reported a hazard ration (HR) of 0.39 (95% CI, 0.28 -0.52;p<0.001) for overall 
survival in favor of chemotherapy . This translates to a benefit of a median of 6 months {Wagner 
2006}.
Performance st atus often declines after first -line therapy . Patients with esophageal cancer often 
have significant comorbidities, including obesity , heart disease, emphy sema, which when 
coupled with progressive dysphagia and malnutrition, often limit therap eutic opportunities after 
first-line therap y. Gastric adenocarcinoma patients who develop peritoneal carcinomatosis often 
have decreased bowel function that then results in GI sy mptoms and a decline in function al 
status and therefore limiting treatment options substantially {Power 2010}. However 
administration of sec ond-line therap y in patients who are sufficientl y fit to receive it has 
demonstrated a survival advantage over supportive care alone. {Kang 2012 , 
Thuss -Patience 
2009 }. A meta -analysis of these studies demonstrated a HR for OS of 0.73 (95%CI, 058 –0.960), 
and in highl y functioning patients (ECOG performance status of 0 or 1) the HR was 
0.57 (95%CI 0.36- 0.91).
For patients who retain an adequate performance status, there is no standard approach for 
second -line the rapy after failure of the first
-line regimen. Quality -of-life and minimization of 
side effects are key  considerations when choosing the therapeu tic approach. The choice of 
regimen is empiric. No single regimen h as emerged as clearly  superior and few trials have 
compared different regimens {Thallinger 2011 , Wesolowski 2009}. Current NCCN guidelines 
suggest clinical trials in the relapsed setting, and immune check point inhibitors have recentl y 
started in these patients.
There is emerging evidence that immunosurveillance is significantly altered in g astroesophageal 
malignancies {Kono 2006, Lu 2011, Ohigashi 2005 }.PD-L1 is a transmembrane protein that 
was first identified for its role in the maintenance of self
-tolerance and prevention of 
autoimmunity  {Fife 2011 }. Engagement of PD -L1 on dendriti c cells with PD -1 receptor on 
Tcells delivers an in hibitory  signal that promotes T -cell anergy  or apoptosis {Keir 2008}.Tumor 
cells overexpress PD -L1 resulting in T-cell anergy and escape from immunosurveillance. 
Blockad e of the interaction between PD- L1 on tumor cells and PD-1 on T cells reverses T -cell 
suppression within tumors, thereb y promoting effective antitumor immune responses. In 
esophageal cancer, tumo r infiltrating l ymphocy tes correlated with improved survival {Kono 
2006 , Lu 2011 }.Of note, 70% of esophageal adenocarcinomas express PD -L1 and its expression 
is independently  associated with worse survival 
{Lu 2011 }.Immune check point inhibitors are 
being activel y investigated in gastric adenocarcinoma and have yielded promising re sults.
There has been earl y demonstration of activit y of PD -1 antibody  immune checkpoint inhibitors 
in upper GI cancers. Pembrolizumab seems to have some activity  in patients with PD -L1 
expressing advanced gastric adenocarcinoma as reported at the European Society  for Medical 
Oncology  2014 meeting {Muro 2014}. Of the 39 patients enrolled, 19 were from Asia and 
20were from other areas of the world. At a median follow up of approximately  6 months, the 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 20 16June 2017ORR was 31% in Asian s and 30% in non -Asians, suggesting activity . Data more recentl y 
presented at ASCO GI in Jan 2016 also confirmed PD -1 inhibition by  nivolumab as an effective 
possibl e treatment strategy for second -line gastric adenocarcinoma patients wi th an ORR of 12% 
andSD of 21%. {Antonia 2015 }.
1.1.2. MMP9 Expression in Oncology
Immunohistochemistry  (IHC)studies conducted with validated reagents indicate that MMP9 
expressio n is highly  prevalent across solid tumors, including gastri c adenocarcinoma 
(
≥90%, n ≥30each for cases of North American, European ,and Chinese origin). MMP9 is 
expressed heterogeneously by tumor epithelia andinfiltrating inflammatory cells (predominantl y 
of my eloid t ype), along with subsets of fibroblastic stroma ,and tumor -associated endothelial 
cells. Heterogeneous expression is apparent within a single tumor, as well as across different 
tumors.   No particular associations with genetic bac kground and MMP9 expression were 
apparent across different solid tumors.
Figure 1-1. Examples of MMP9 Expression in Gastric Adenocarcinoma (IHC)
Panels on the left show examples of regions with high tumor cell epithelial positivity for MMP9, along with positive stromal 
areas. In panels on the right, there is less MMP9 expression evident in tumor epithelia, but stromal positivity is apparent. All 
cases contain MMP9 -positive infiltrating inflammatory cells.  
1.1.3. General Information
Andecaliximab (formerl y GS -5745) is a recombinant chimeric IgG4 monoclonal antibody 
selective for MMP9. It has been engineered to remove T cell epitopes in an effort to reduce the 
risk of immunogenicit y. Andecaliximab was derived from the murine anti -human MMP9 
monoclonal antibody ,AB0041, and shares the same binding characteristics. Andecaliximab and 
AB0041 cross -react with and inhibit rat and cy nomolgus monkey  MMP9 but not murine MMP9. 

Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 21 16June 2017AB0046, which cross -reacts with and inhibits murine MMP9, was generated via immunization in 
MMP9 knockout mice. Epitope mapping anal ysis revealed that AB0046 binds a similar region in 
murine MMP9 to that bound by  andecaliximab and AB0041 on human MMP9. 
For further information on andeca liximab , refer to the current Investigator’s Brochure (IB).
1.1.4. Preclinical Pharmacology and Toxicology
1.1.4.1. Pharmacology
MMP9 enzymatic activity  contributes to tumor growth by  several mechanisms (Figure 1-2).
MMP9 degrades basement membrane collagen and remodels other extracellular matrix (ECM) 
components and regulates the bioavailability  of ECM -sequestered growth factors such as VEGF, 
FGF-2, as well as membrane -tethered EGF {Ardi 2009 , Dery ugina 2010 , Kessenbrock 2010 , 
Perng 2011 }.
Proteol ytic breakdown of phy sical bar riers to cell invasion plus liberation of 
factors that activate growth and angiogenesis paves the way  for tumor expansion and metastasis, 
with the accompan ying development of neovascularization to support tumor outgrowth. MMP9 
expression by  tumor -associate d myeloid suppressor cells (MSCs) such as macrophages (TAMs), 
neutrophils (TANs), and myeloid -derived suppressor cells (MDSC) is associated with local pro -
tumorigenic immunomodulation and angiogenesis {Farina 2014 }.Cytokine and chemokine 
modulation by  MMP9 in the tumor microenvironment promotes further recruitment of MSCs 
that both promote tumor growth and reduce anti-tumor immune responses by  T and NK cells
(Figure 1-
2) {Condeelis 2006 , Heissig 2002 , Shih 2006 }.
Figure 1-2. Summary of Pro -Tum origenic Activities of MMP9
Summary of pro -tumorigenic activities of MMP9, which include promoting tumor growth, invasion, and metastasis via effects on 
both tumor epithelia and the microenvironment. Remodeling of the microenvironment alters the physical properties of tumors. I n 
addition, the action of MMP9 on cytokines and chemokines in the local milieu promote recruitment and activation of myeloid 
suppressor cells and inhibit anti -tumor T -cell recruitment and responses.
_ _ e growth 
- . factors 
r 
I Reduce Tcell 
recruitment , 
activation 
ANTI-TUMOR 
T-CELL 
- · lr !CXCL9 
!iCXCL10 
!CXCL11 
Alter MSC 
cytokines , 
chemokines Increase MSC 
recru itment , 
activation INFLAMMATORY FILTRATE 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 22 16June 2017The therapeutic potential of inhibitory  antibodies targeting human MMP9 (AB0041) and mouse 
MMP9 (AB0046 ) was evaluated in a surgical orthotopic xenograft mouse model of colorectal 
carcinoma in which tumors were derived from the human tumor cell line HCT116. While MMP9 
expression is limited in this tumor model as compared to human gastroin testinal tumors such as 
gastric and colorectal cancer, with patchy positivity in subsets of tumor epithelia and infiltrating 
myeloid cells observed, the model nonetheless enables exploration of MMP9 biology  in each 
compartment. Treatment of established tumors with a cockt ail of an anti -human MMP9 antibody  
(targeting MMP9 produced by  tumor epithelia) and an anti -mouse MMP9 antibody  (targeting 
MMP9 produced b y infiltrating cells) significantly  reduced growth of the primary  tumor and 
reduced the incidence of metastases in multiple independent studies. Furthermore, t reatment with 
either agent alone yielded significant anti -tumor efficacy  highlighting important role sfor both 
tumor epithelial -derived and stromal/infiltrate -derived MMP9 in primary  tumor outgrowth . Of 
note, in addition to reduction in tumor growth, MMP9 inhibition was associated with changes in 
the tumor microenvironment, specificall y a reduction in the tumor cell -associated fibrillar 
collagen as measured b y second harmonic generation microscopy , amultiphoton method that 
specificall y visualizes crystalline fibrillar collagen (Figure 1-3). Follow up studies in the 
orthotopic HCT -116 model provide further e vidence that inhibition of MMP9 -associated 
remodeling can promote delivery  of agents to the tum or (in this example, modeled b y injection 
and imaging of doxorubicin after 2 w eeks of therapy  with anti -MMP9, Figure 1-4). 
Figure 1-3. Changes in Tumor -Associated Fibrillar Collagen
Changes in tumor -associated fibrillar collagen (second harmonic generation microscopy, white) with MMP9 inhibition in an 
orthotopic model of colorectal cancer (HCT -116-derived) . T = tumor, N = normal. Fibrillar collagen adjacent to normal structures 
was not altered, but tumor -associated fibri llar collagen was reduced.
lgG control aMMP9 mAb 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 23 16June 2017Figure 1-4. Effect of MMP9 Inhibition in the HCT -116 Orthotopic Model of CRC
Exploring the effects of MMP9 inhibition in the HCT -116 orthotopic model o f colorectal cancer, in which tumor cells are labeled 
with green fluorescent protein (GFP, in green) and the host is labeled with cyan fluorescent protein, with bias towards fibro blastic 
cells (CFP, in blue). After two weeks of treatment of established tum ors with anti -MMP9 antibodies or an is otype control, 
doxorubicin is administered and its natural signal imaged 24 hours later (red). The merged image highlights changes in the 
physical tumor structure with anti -MMP9, along with evidence of improved deliver y of doxorubicin.
These observations and published data suggest that inhibition of MMP9 could provide benefit 
with respect to anti -tumor immunity  in 2 respects: improved access of both antibodies and 
Tcells themselves to tumor cells to enable s ynapse form ation and cell ly sis as a result of 
remodeling of the tumor microenvironment, and re -balancing of a m yeloid -rich tumor -associated 
cellular milieu to one that is less r epressive to cy totoxic T -cell entry and activity  (Figure 1-5). To 
experimentally  explore these concepts, a s yngeneic mouse model of breast cancer was utilized 
(HC11 -NeuT [ HER2 ]-driven tumors implanted in the mammary  fat pad). IHC analy sis of 
HC11 -NeuT tumors indicated that MMP9 expression was restricted to the myeloid cell infiltrate 
with limi ted to no expression apparent in tumor epithelia ( Figure 1-6). While this expression 
pattern underestimates the MMP9 profile that is observed in human tumors, it nonetheless 
affords an opportunity  to examine the consequences of inhibiting my eloid -derived, 
tumor -associated MMP9 in mice with an intact immune sy stem. As shown in Figure 1-6, 
therapeutic administration of anti -murine MMP9 antibody  AB0046 resulted in significant 
inhibition of tumor growth, highlighting the role of myeloid cell -derived MMP9 in promoting 
tumorigenesis. Conversely , a murine inhi bitory  antibody  targeting the T -cell checkpoint pathway  
via PD -L1 did not have any  impact on tumor growth. The resistance to checkpoint thera py in this 
model is attributed to the presence of MSC. A combinat ion of anti -MMP9 and anti -PD-1 did not 
further impact tumor volume in this model, perhaps in part due to the magnitude of effect of 
anti-MMP9 as a single agent.
Tumor (GFP) Doxorubic in Host (CFP) MERGE 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 24 16June 2017Figure 1-5. Hypothesis for Andecaliximab and Ni volumab
Hypothesis for the combination of andecaliximab with nivolumab (figure adapted from Gajewski et al Nature Immunology, 
{Gajewski 2013 }). Treat ment with andecaliximab could convert “type b” tumors with dense fibrotic stroma, high myeloid 
suppressor ce ll contact, and deficiency of T- cell infiltration into “type a” tumors in which T -cell entry is enabled via remodeling 
of the microenvironment and re -balancing of suppressive myeloid -derived cytokines and chemokines. T cells in “type a” tumors 
are susceptible to checkpoint inhibition, wh ich is overcome by treatment with nivolumab.
Figure 1-6. Inhibition of MMP9 in Orthotopic HC11 -NeuT Model of Breast 
Cancer
Inhibition of MMP9 is efficacious in the syngeneic, orthotopic HC11 -NeuT model of breast cancer. Treatment was initiated at an 
average tumor volume of 100 mm3. Test articles: vehicle (blue), Isotype control IgG (GS -645864, red), anti -MMP9 
(GS-622703 = AB0046, green), anti -PD-L1 (GS -696882, purple), combination of anti -MMP 9 and anti -PD-L1 (orange). 
**p< 0.01 , *** p < 0.005. Representative IHC for MMP9 expression in this model is shown in C, positive myeloid cell 
infiltrate.
A. 
-10 a 
Tryptophan 
dep!ebon ______ ____ _, 
Tumor Volume (median+/-S EM) 
(") 
E 
E 
Q) 
E 
::::, 
0 > 
10-.l!::l5-~~ ~f---..,i1 
i= 
0 
...... 10 
Days 20 
lsotype Control 30 I") 
E 
E 
cu 
E ::, 
0 > ... 
0 
E ::, I-i 
Vasculature 
B. Tumor Volume (Individual) 
!: !: !: I *** 1000 
800 T 
• T 600 ·-A w • 400 ::: i 200 •• •• • T ., . 
0 • 
... a-PDL 1 C. IHC for MMP 9 
a-MMP9 _,._ a-MMP9/a..PDL 1 
...... Vehicle 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 25 16June 2017Collagen fibrils around tumors can impede delivery of therapies and the access of T cells to 
tumor cells, thus a cting as a phy sical barrier to anti -tumor immunity  and contributing to tumor 
progression . Anal ysis of tumor -associated fibrillar collagen b y second harmonic microscop y was 
superimposed with images of nuclear staining (Sytox orange) and tumor cell staining 
(cytokeratin) to provide context for collagen fibril visualization . The cy tokeratin staining 
revealed that the tumors grew in both large masses and small acinar structures and the collagen 
fibrils in and around both structures appeared to be diminished in the tumors treated with 
AB0046 ( Figure 1-7). Quantification of fibrillar collagen intensit y across entire images from this 
study  confirmed the trend in decreased fibrillar collagen in the α -MMP9 treated tumors. 
Figure 1-7. Changes in Tumor -Associated Fibrillar Collagen
Changes in tumor -associated f ibrillar collagen (second harmonic generation microscopy, white) with MMP9 inhibition in an 
orthotopic syngeneic model of breast cancer. Tumor c ells are stained with a pan -cytokeratin marker (pink), nuclei in DAPI 
(blue).
Transcript and pathway  analy sis of treated tumors revealed additional changes in the tumor 
microenvironment associated w ith MMP9 inhibition. The top 10 pathway s anal ysis using C2
canonical pathway s collections indicated that inhibition of MMP9 lead to an increase in overall 
immune signature pathway s such as interferon gamma and alpha -beta signaling, 
immunoregulation, antigen processing and presentation, and CD8 and T -cell receptor signaling. 
For anti -PD-L1 treated tumors, an increase in immune signature was also observed, consistent 
with the known mechanism of action of this agent (immunoregulatory  interactions between 
lymphoid and non -lymphoid cells, CD8 TCR pathway , TCR pathway ,and T -cell signal 
transduction). As illustrated in Figure 1-8, upregulation of immunomodulatory  pathway s 
consistent with T -cell and possibly  also NK cell activation was a notable feature of MMP9 
inhibition by  different pathway  anal yses, and these patterns were also reflected in the PD -L1 and 
combination groups. These data are consistent with inhibition of my eloid -produced MMP9 
resulting in a microenvironme nt that is more favorable for T -cell infiltration and activation. 
lgG control aMMP9 mAb 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 26 16June 2017Figure 1-8. Transcriptome and Pathway Analysis of the HC11 -NeuT Model
Primary pathways for MMP9 inhibition, from KEGG and Broad colle ctions, reflect activation of T -cell and related 
immunomodulatory signaling pathways. 
The PD -1/PD -L1 axis defines an immune checkpoint that prevents the activation of T cells in the 
tumor microenvironment. Data from current clinical trials suggests that the tumors that respond 
most strongly  to nivolumab are those that are either particularl y immunogenic (eg, tumors with 
genomic instability) or those with infiltrated T cells in the tumor. For tumors that do not respond, 
despite the relief of the immune checkpoint b y nivol umab, continued repression of T -cell 
activation due to an immunosuppress ive environment may  be a possible explanation. 
andecaliximab is hy pothesized to remove the immunosuppressive environment through local 
suppression of or reduction of my eloid -derived suppressor cells, as well as local inflammation 
and immunosuppressive cyto kines. Additionally , inhibition of MMP9 in the tumor 
microenvironment is expected to promote l ymphocy te and therapeutic access. Thus, combination 
of andecaliximab with nivolumab is proposed to lea d to more activated cy totoxic T cells and 
provide superior e fficacy in advanced gastric cancer relative to nivolumab alone.
The major dose limiting toxicity  observed in clinical studies with pan -MMP inhibitors, such as 
marimastat, was musculoskeletal sy ndrome (MSS ) consisting of tendonitis manifested b y joint 
stiffness, edema, reduced mobility , and skin discoloration. A study  to evaluate the potential of an 
anti-MMP9 antibody  to induce MSS was conducted in Lewis rats. Unlike the pan -MMP 
inhibitor, Marimastat, AB0041 did not induce any evidence of MSS or other toxici ties in this
Lewis rat MSS model.
Further details on the non -clinical pharm acology  are available in the andecaliximab IB.
A 
12 3 
1 = aPDL1 
2 = combination 
3= aMMP9 
123 1 = aMMP9 
2 = com bi nation 
3=aPDL1 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 27 16June 20171.1.4.2. Toxicology
The toxicology  program consists of completed 4 -week repeat -dose IV toxicity  studies in both 
rats and monkey s. The 26 -week toxicity  studies in rats and cy nomolgus monkey s included both 
IV and SC routes. The rat and rabbit embry o fetal development studies and the rat fertility  study  
have also been completed. At doses of andecaliximab up to 100 mg/kg/dose IV, data indicate no 
test article -related maternal or fetal effects in rats and rabbits, and no test article -related effects 
on male or female fertility  in rats. Findings associated with andecaliximab treatment in the 
4-week repeat -dose toxicity  studies have been limited to reversible physeal hy pertrophy  in rats , 
and reversible increased adrenal gland weight in female monkey s at all doses, which was 
associated with slight h ypertroph y of the zona fasciculata in a single 100 -mg/kg/dose female 
monkey .The phy seal h ypertroph y inrats is likely directly  attributable to inhibition of MMP9 as 
similar findings were observed in MMP9 null mi ce {Vu 1998} and in children with mutations in 
MMP9 and MMP13 {Lausch 2009}. In both mice and children, this is a transient finding that 
spontaneously
 regresses as the bone matures. The phy seal hy pertroph y noted in rats is not 
considered relevant to adult humans because the growth plates are closed and longitudinal bone 
growth is no longer ongoing in adults. In the 26 -week studies, there were no findings of 
toxicological concern in rats or cy nomolgus monkey s following weekl y IV or SC administration 
at doses up to 100 mg/kg/dose and 150 mg/kg/dose, respectivel y. The lack of physeal 
hypertrophy  observed in the rat 26 -week study  is presumabl y due to the reversible nature of this 
finding as longitudinal bone growth and growth plate closure slows/completes. The NOAEL in 
the ra t and monkey  26
-week studies was 100 mg/kg/dose (IV) (Rat Week 24 AUC 0-168h269,000; 
monkey  Week 25 AUC 0-168h766,000 µg•h/mL) and 150 mg/kg/dose (SC), (Rat Week 24 
AUC 0-168h101,000 µg •h/mL ; monkey  Week 25 AUC 0 -168h719,000 µg•h/mL), respectivel y, the
highest doses evaluated by each route of administration in each stud y.
1.1.5. Clinical Trials of Andecaliximab
Andecaliximab is being investigated for the treatment of solid tumors, inflammatory bowel 
disease, rheumatoid arthritis, cy stic fibrosis, and chronic o bstructive pulmonary  disease. Brief 
summaries of the solid tumor clinical trials are provided herein.
Study  GS-US-296- 0101 is a Phase 1, open -label, sequential dose -escalation, and expansion study  
to evaluate safet y, pharmacokinetics ( PK), and pharmacody namics of andecaliximab following 
multiple I V administrations of andecaliximab alone (at 200, 60 0, and 1800 mg every  2weeks 
[Q2W ]) or in combination with chemotherap y (at 800 mg Q2W or 1200 mg every  3 weeks 
[Q3W ]) in subjects with advanced solid tumors.
As of January  12, 2016, Study  GS-US-296-0101 had enrolled 40 subjects with metastatic gastric 
adenocarcinoma (14 remain on study ). Grade 3 or higher treatment- emergent AEs (TEAEs) 
included neutropenia (18%), nausea (10%), and neutrophil count decreased (10%). The most 
common serious TEAEs were abdominal pain, GI hemorrhage, h yponatremia, nausea, p yrexia,
and sept ic shock each occurring in 2 subjects (5%). Median progression free survival (PFS) for 
all 40 subjects was 7.4 months (90% confidence interval (CI) = [5.0, 12.5]), with a median 
duration of response (DOR) of 9.4 months and an objective response rate (ORR) of 50%. Of 
those subjects, 30 were chemotherap y naïve (eg, first- line), and demonstrated a median PFS of 
12.0 (90% CI=[5.5, 18.0]) months, with a median DOR of 10.6 months and an ORR of 57%. 
Collagen neoepitope decreased with c ontinued treatment, demonstrating on-target effects. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 28 16June 2017This efficacy  data combined with the favorable safety  profile continues to supp ort evaluation of 
andecaliximab in a Phase 3 study  of this fatal disease where therapeu tic options are limited and 
non-curative.
Study  GS
-US-296- 1080 is a Phase 3, randomized, double -blind, placebo -controlled study  to 
evaluate the efficacy  and safet y of andecaliximab in com bination with mFOLFOX6 as first -line 
treatment in subjects with advanced gastric or GEJ adenocarcinoma. A dose of 800 mg Q2W in 
combination with mFOLFOX6 is being evaluated globall y at centers in the United States, 
Europe, Latin America ,
and Australia. 
Study  GS US -296- 1884 is a Phase 1b clinical study  of Japanese subjects to evaluate safet y and 
tolerability  of GS5745 as 
monotherap y and in combination with chemotherapy.
Further details on the oncology  studies with andecaliximab , as well as the clinical studies outside 
of oncology ,can be found in the andecaliximab IB.
1.1.6. Information about Nivolumab
Nivolumab ( OPDIVO )is a programmed death receptor -1 (PD -1) blocking antibody  indicated for 
thetreatment of patients with:
Advanced (unresectab le or metastatic) melanoma in adults
Metastatic non -small cell lung cancer whose disease progressed during or after 
platinum -based chemotherap y.(US FDA)
Advanced renal cell carcinoma who have received prior anti -angiogenic therapy  (US FDA)
Please see loc al label for updated accurate information about nivolumab.
1.2. Rationale for t his Study
Andecaliximab is a monoclonal antibody that inhibits MMP9, an extracellular enzy me involved 
in matrix remodeling, tumor growth, and metastasis. Preclinical studies demonst rate that MMP9 
inhibition alters the tumor microenvironment, is associated with greater chemotherapy  
penetration ,and improved anti -tumor immunity .
MMP9 has been shown to degrade and remodel basement membrane and extracellular matrix 
and vasculature. It ca n promote recruitment of tumor -associated macrophages and immune 
suppressor cells, and locally  activate cy tokines produced by  these cells that impair anti -tumor 
immunity . The murine surrogate of andecaliximab (anti-MMP9 antibody ) has shown significant 
anti-tumor activity  in models in which MMP9 is produced by  infiltrating my eloid cells. The 
anti-tumor activity  is associated with reduction of tumor -associated fibrillar collagen, and 
alterations in the immune cell transcript pr ofile in the treated tumors. PD -1 is a negative 
co-stimulatory  receptor expressed primarily  on act ivated T cells. Binding of a PD -1inhibitor to 
the PD -1 receptor will inhibit the inhibitory  signal on T cells and will thus stimulate 
the 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 29 16June 2017anti-tumor effect. Andecaliximab ’s ability  to alter the collagenous microenvironment may  allow 
for greater infiltration of activated l ymphocy tes into the t umor and hence augment the anti- tumor 
effect offered b y a PD- 1 inhibitor alone. Thus, the combination of removing the negative 
stimulus on T cells by  the PD-1 inhibitor and the enabling of activated T cells to gain access to 
the tumor cells by  remodeling of the microenvironment and reduction of suppressive signals 
makes this a very  attractive combination for cancer therapy . 
Nivolumab is a fully  human ant i-PD-1 IgG4 monoclonal antibody  with a favorable safety  profile 
and efficacy  in melanoma, non –small -cell lung cancer, and renal cell carcinoma. The Phase 1/2, 
open -
label CheckMate- 032 study  evaluated nivolumab ± ipilimumab in subjects with solid 
tumors. At GI ASCO 2016 data were presented for subject s with gastroesophageal or gastric 
adenocarcinoma receiving nivolumab monotherapy. Fifty-nine subjects were enrolled and treated 
with single -agent nivolumab; ORR was 12% (n = 7/58; 1 complete response, 6 partial responses , 
12 subjects [21%] had stable disease ).Among responders, median duration of response was 
7.1months (95% CI , 3.0–13.2) andOS was 6.8 months (95% CI , 3.3–12.4 ). Thirty -nine percent
of tumo
r samples were PD -L1 positive ( ≥ 1% cutoff). ORRs in subjects with PD -L1-positive and 
-negative tumors were 18% and 12%, respectivel y. The investigators concluded that nivolumab 
showed activity  in second -line 
gastric adenocarcinoma and should be further investigated.
Somatic mutations have the potential to enco de for “non- self” and serve as immunogenic 
antigens. Tumors with a large number of somatic mutations due to genomic instability  have been 
found to be more susceptible to immune checkpoint blockade. In a trial of 41 subjects with 
progressive metastatic carc inoma with or without mismatch -repair deficiency , both PFS and OS 
were significantly  improved for subjects treated with a PD -1 inhibitor alone and whose tumors 
were genomicall y unstable {Le 2015 }.
Randomization in this study  will be stratified b y PD-L1status
.
1.3. Risk/Benefit Assessment for the Study
There is no clear or demonstrably  superior standard regimen for the treatment of advanced 
gastric adenocarcinoma especi ally for those who failed first -line chemotherapy ; however, further 
therap y does improve OS.  Prelimina ry data shows that immune check point inhibitors have 
activity  in this difficult disease and with fewer side effects than che motherapy . Furthermore, 
many  patients cannot take second- line and bey ond chemotherap y due to deterioration of 
performance status or other comorbid conditions and thus immune therapy  presents an attractive 
option for them. A ndecaliximab has the potential to augme nt the response by  immune checkpoint 
inhibitors in 3 distinct ways: (1) allow gre ater penetration of activated T cells into the tumor bed 
by remodelin g the extracellular matrix, (2) inhibit the MDS Cs that are present due to MMP 9 
physiologic activit y,and (3) change the cy tokine milieu to be predominantly  anti-tumor. This 
preclinical h ypothesis has been tested in mouse models and presents as strong rationale for 
efficacy  in human cancer. 
Furthermore, andecaliximab thus far has shown limited toxicity  in clinical trials. No MTD dose 
was reached in t he dose -escalation monotherap y Phase 1study , and the toxicity  profile seen 
when combining andecaliximab with mFOLFOX chemotherap y is similar to that seen with 
chemotherap y alone.  To date t here have been no a dditional toxicities ascribed to andecaliximab . 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 30 16June 2017Preliminary  clinical data point to activity  of andecaliximab in combination with chemotherap y 
with a median PFS in chemotherap y-naive subjects of 12 months. Early  data similarly  shows 
activity  of nivolumab a s monotherapy  in the refractory  gastric adenocarcinoma population with 
durable response rates and a tolerable safet y profile (G rade 3 or 4 treatment -related AEs in ~17% 
of subjects in the most recent public data from CheckMate-032) . It is hy pothesized that the 
2agents together, andecaliximab and nivolumab ,will have greater activity  when combined. 
Potential risks are those inherent in participation in any  clinical trial, including (but not limited to)
the potential for unforeseen toxicity  from 1or more o f the study  treatments, procedure -associated
risks for protocol -specified procedures, and potential to be treated with a less -active therap y 
regimen.
The favorabl e nonclinical and clinical data outweigh the risks associated with administration of 
andecalix imab and nivolumab and support the evaluation of andecaliximab in combination with 
nivolumab as a second -line treatment in subjects with advanced gastric or GEJ adenocarcinoma.
1.4. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
Andecaliximab (fo1medy GS-5745 ) 
Protocol GS-US-296 -2013 
Gilead Sciences , Inc. 
2_ OBJECTIVES 
The prima1y object ive of this study is: Final 
Amendment3 
• To evaluate and compa re the efficacy of andecaliximab in comb ination with nivolumab 
versus nivolumab alone in subjects with recune nt gastr ic or GEJ adenocarcinoma 
The secondaiy object ives of this study ai·e: 
• To chai·acte rize and compai·e safety and tolerabi lity of andecaliximab in combination with 
nivolumab versus nivolumab alone in subjects with recunent gastric or GEJ adenocai·cinoma 
• To chai·acterize the phannacokinetics (PK) of andecaliximab in comb ination with nivolumab 
The explorato1y objectives of this study ai·e: 
I 
I 
I 
I 
I 
CONFIDENTIAL Page 31 16 June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 32 16June 20173. STUDY  DESIGN
3.1. Endpoints
The endpoints of this study  are described in Sections 8.1.2 ,8.1.3 ,and8.1.4 . 
3.2. Study Design
This is a Phase 2, open -label, randomized study  comparing andecaliximab in combination with 
nivolumab versus nivolumab alone in recurrent gastric adenocarcinoma . One hundred and 
twenty subjects (60 per arm) will be randomized to either Treatment Arm A: 
andecaliximab + nivolumab or T reatment Arm B:  nivolumab alone . 
To evaluate combination drug safet y, an independent Data Monitoring Committee (DMC) will 
be charged with overseeing the stud y safet y. After the first 20 subjects are treated for 12 weeks, 
theDMC will review and evaluate all safet y data for an y unexpected toxicities. If the DMC 
determines the combination demonstrate sacceptable tolerability , enrollment and randomization 
will proceed with continued safet y oversight from the DMC. Thereafter, rev iew of safet y data 
will be performed at regular intervals as described in the DMC charter.
Treatment Groups:
Arm A: andecaliximab + nivolumab
Arm B: nivolumab
Randomization and Stratification:
1:1 allocation to andecaliximab + nivolumab versus nivolumab alone through an interactive 
web response sy stem (IWRS)
Fixed -block centralized randomization with stratified by : 
PD-L1 positive versus PD-L1 negative
I 
1 Arm A I 
1 N=60 GS-5745 + Nivolumab 
(Up to 2 years) : I Long-Term Follow-Up > 
I 
1 Arm B Nivolumab 
1 N=60 L_....J. ,::.Uc..:;to:..::..&.2e;;.;a;.;.rs;;..:.)_1 I 
I 
StratifiJation and 
Randomization Disease 
progression or 
study stopped Long-Term Follow-Up > 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 33 16June 20173.3. Study Treatments
Subjects meeting eligibility  randomized to Arm A will receive 800 mg of ande caliximab on 
Day 1and every  2 weeks thereafter via intravenous (IV) infusion over approximately  30minutes
in advance of nivolumab . N ivolumab (3 mg/kg) will be administered via IV infusion over 
approximately  60minutes following the completion of andecaliximab administration
.
Subjects meeting eligibility  randomized to Arm B will receive 3 mg/kg nivolumab via IV
infusion over approximately  60 minut es on Day  1and every  2 weeks 
thereafter.
3.4. Duration of Treatment
Starting on Day  1, treatment will be g iven every  2 weeks and will continue in the absence of 
disease progr ession or unacceptable toxicity , consent withdrawal or subject’s refusal of 
treatment ,or up to 
2 years. There will be a screening period of up to 28 days. Following 
completion of treatmen t, subjects will be followed for safety  at30daysafter last dose of 
andecaliximab and5months post-treatment of nivolumab
,andforsurvival status approximately  
every  3 months for up to 5 y earstotal.
3.5. Discontinuation Criteria from Treatment 
Andecaliximab and/or nivolumab will be discontinued f or an y of the following reasons:
Pregnancy during the study ; refer to Appendix 4
Investigator decision to remove the subject from the study  treatment, in consultation with the 
Gilead Medical Monitor whenever possible
Confirmed disease progression (see Section 6.2.9 Disease and Response Assessment)
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree
Initiation of non -study  specific anti -neoplastic therapy  
Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or 
toxicity  that, in the judgment of the investigator, compromises the ability  to continue 
study -specific proced ures or is considered to not be in the subject’s best interest
Subject request to discontinue treatment
Withdrawal of consent 
Death
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 34 16June 2017Discontinuation of the study  at the request of Gilead, a regulatory  agency , or an 
institutional review board or independent ethics committee (I RB/IEC)
Lost to follow up
Subject non -compliance
Should 
any study  medication discontinuation occur, the reason for discontinuation should be 
entered in the corresponding study  drug completion eCRF . In addition, the subject should 
contin ue with the rest of the treatment regimen and the study  related procedures per protocol.
3.5.1. Discontinuation Criteria for Nivolumab
In addition to the discontinuation reasons outlined in S ection 3.5, please refer to the current 
nivolumab label or SmPC for y ourrespective region forfull discontinuation criteria during 
treatment with nivolumab.
Nivolu mab should also be discontinued for an y dosing interruption lasting > 6 weeks with the 
following exceptions:
Dosing interruptions to allow for prolonged steroid tap ers to manage drug -related AEs are 
allowed. Prior to re -initiating treatment in a subject with a dosing interruption lasting
>
6weeks, the Sponsor Medical Monitor/Study  Director must be consulted. Tumor
assessments should continue as per protocol even if dosing is interrupted.
Dosing interruptions > 6 weeks that occur for non -drug-related reasons may be allowed if
approved b y the Sponsor Medical Monitor/Study Director. Prior to reinitiating treatment in a 
subject with a dosing interruption lasting > 6 week s, the Sponsor Medical Monitor/Study  
Director must be consulted. Tumor assessments should continue as per protocol even if 
dosing is interrupted.
If nivolumab therap y is permanentl y discontinued for an y reason, subjects on Treatment Arm A 
should also perma nentl y discontinue andecaliximab therap y at the same time.  Subjects enrolled 
on Treatment Arm A who discontinue andecaliximab for reasons other than progression may  
continue nivolumab after consultation with the Sponsor Medical Monitor/Study  Director.
3.6. Premature Discontinuation from Study Treatment
If a subject has discontinued all study  treatments prior to definitive disease progression, the 
subject shall remain on study  until at least 1 of the criteria for discontinuation from study  is met
(Secti on3.7). Every  attempt should be made to keep the subject in the study  and continue to 
perform tumor evaluation by computed tomography  (CT) or magnetic resonance imaging ( MRI ) 
every 8 weeks until disease progression
. If this is not possible or acceptable to the subject or 
investigator, the subject may  be withdrawn from the study . It is recommended that the 
investigator consults with the medical monitor prior to removing the subject from study  for any  
reason except subject withdrawal of consent.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 35 16June 20173.7. Discontinuation Crite ria from Study
Subject study  participation, may  be ended due to any  of the following reasons:
Initiation of non -study  specific anti -neoplastic therapy  in the absence of progression
Disease progression
Intercurrent illness that would, in the judgment of the investigator, affect assessments of
clinical status to a significant degree
Withdrawal of consent
Investigator decision to remove the subject from the study , in consultation with the Gilead 
Medical Monitor
Death
Discontinuation of the study  at the request of Gilead, a regulatory  agency , or an IRB/ IEC
Lost to follow up
3.8. Long -Term Follow -Up for Overall Survival 
Long-term follow -up (LTFU) will be initiated for subjects who discontinue participation in the 
study  due to reasons other than death. The subject shall remain on LTFU for OS until: 
Death 
Withdrawal of consent to participate in LTFU
Lost to follow up
End of LTFU period 
Every attempt should be made to keep the subject in the LTFU for OS.
The end of the trial will be defined as when all subjects have completed LTFU or discontinued 
their participation in the study  due to death, withdrawal of consent ,or lost to follow -up.
3.9. Source Data
The subject identification number and randomization number captured by the interactive
web response sy stem (IWRS)are considered source data .
Andeca liximab (fo1medy GS-5745 ) 
Protoco l GS-US-296-2013 
Gilead Sciences , Inc. 
3.10. Biomarker Testing Final 
Amendment3 
The PD-1 /PD-Ll axis defines an immun e checkpoint that preven ts the activation of T cells in the 
tumor microenvironmen t. Nivolumab inhibits binding of T-cell PD-1 to PD-Ll present on tumor 
and stromal cells; thus nivolumab inhibits the ch eckpoint to allow activation of cytotox ic T cells 
by tumor immun ogens. D ata from c mTent clinical trials su ggests that the tumors that respo nd 
most strongly to nivolumab are those that are either immun ogenic (tumors with genomic 
instability) or th ose with infiltrated T cells in the tumor. For tumors th at don 't r espond, despite 
the re lief of the immun e checkpoint by nivolumab, continu ed repression of T- cell activation due 
to an immun osuppr essive environm ent m ay be a possibl e explanation. Andecaliximab is 
hypothesized to rem ove the immun osuppr essive environm ent through l ocal sup pression of or 
reduction of m yeloid su ppressor cells, local inflamm ation, and immun osuppressive cytokines. 
Additiona lly, inhibiti on ofMM P9 in the tumor microenvironment is expec ted to promote 
lymph ocyte and therapeutic a gent access. Thus, combinati on of andeca liximab with nivoluma b is 
propose d to lead to more a ctivated cytotoxic T cells and provide superior efficacy in advanced 
gastric adenocarcinoma rel ative to nivolumab alone. The biomarker testing descr ibed below is 
designed to address, to the extent possib le, these specific hypotheses and to investigate whether 
non-invasive bioma rkers of response can be identified. 
3.10.1. Biomarker Samples to Addre ss the Study Objectives: 
Biological spec imens w ill be collected in this study and will be used to evaluate the assoc iation 
of explorato1 y syste mic and/or tissue sp ecific bioma rkers w ith study drng response, includin g 
efficacy and/or AEs and to increase knowledge and understa nding of the biol ogy of gastric 
adenocarcinoma and/o r the validation of a compani on diagnostic for andeca liximab. The specific 
analyses may include, but w ill not be limited to, the biomark ers and assays listed below. Because 
bioma rker science is a rapidly evolving area of investigation, and AEs in paiiicular ai·e difficult 
to predict, it is not possibl e to specify prospect ively all tests that will be done on the spec imens 
prov ided. The testing is b ased upon the c mTent state of scientific knowledge . It may be mo dified 
dmin g or after the end of the s tudy to remove tests no lon ger indicated and/or to add new tests 
based upon the grow ing state of a1i knowledge . Any futm e testing must be approve d by local 
autho rities as applicable acco rding to specific local regulations. 
3.10.1.1. PD-Ll Biomark er Test for Stratification 
PD-Ll will be assessed by immun ohistochemistiy (IHC). Arc hival tumor tissue is r equired, 
prefera bly from the most recent available biopsy or smgi cal resectio n. Archival FFPE blocks ai·e 
prefeITed. The centi·al laborato 1 y pathologist w ill ce1 i ify the pr esence of sufficient t umor tissue. 
Tum or tissue is al so requested for other biomai·ker tests in Table 3-1. 
CONFIDENTIAL Page 36 16 June20 17 
Andecalixima b (fo1me d y GS-5745) 
Protocol GS-US-296 -2013 
Gilead Sciences, Inc. 
3.10.1.2. Phaimacody namic Biomai·kers 
-
CONFIDENTIAL Page 37 Final 
Amendment3 
16 June20 17 
Andecaliximab (fo1medy GS-5745) 
Protocol GS-US- 296-2013 
Gilead Science s, Inc. Final 
Amendment3 
Tabl e 3-1. Biomark er Objectives and Testing 
SAMPLE TYP E 
Tissue Biop sy 
(archi val): Most recently OBJECTIVE 
obtained archi val tumor Stratification MANDATORY 
biopsy 
Required 
To evaluate poten tial baseline marker s 
that con-elate with respon se 
Tissue Biop sy: 
On-treatment ( obtained To evaluate potential markers that 
betv.•een Wee ks 5-9) con-elate with treatment and/or response 
Required 
Tissue Biop sy: At 
Progre ssion To evaluate potential marker s of acquired 
resista nce If medically feasible 
To evaluate phannacodynamic markers 
of andecalixim ab 
To evaluate inflammation and 
chemokine s related to T-cell activation 
and other protein markers ofMMP9 
activity 
Blood To evaluate circula ting immune cells 
To evaluate the impact of treatmen t 
and/or response on tumo r heterogeneity 
To evaluate disease burden and identify 
muta tions con-elated with resistance to 
therapy 
Oral sample To investigate oral microbiome diversity 
CONFIDENTIAL Page 38 TEST 
• P D-Ll IHC 
• MMP9 , other MMP s and Immune Cells 
by IHC and other method s 
• Tumor gene expre ssion (RNA ); IFNy 
gene signature , immune cell signature s, 
• Genomic instability 
• Somatic tumor DNA mutation s 
• MMP9 , other MMP s, PD- Ll and 
Immune Cells (to include MDSCs and 
proliferating T cells) by IHC and other 
method s 
• Tumor gene expression pattems (RNA) ; 
IFNy signature , immune cell signa tures, 
• MMP9 , other MMP s and Immune Cells 
• Tumor gene expre ssion pattem s (RNA ); 
IFNy signature , immune cell signa tures 
• MMP9 -mediated collagen cleavage 
product s (ClM) 
• Circulating cytokines , chemokine s and 
inflammatory markers 
• Immune cell phenotyping by flow 
cytometry 
• Immune cell repertoire 
• Genomic analy sis of circulating tumo r 
cells 
• Circulating tumor DNA ( ctDNA ) 
isolation and sequencing 
• Characteriz ation of oral microbiome 
diversity 
16June201 7 
Andecalixima b (fo1medy GS-5745) 
Protocol GS-US-296 -2013 
Gilead Sciences, Inc. 
3.10.2. Biologic Sample s for Optional Future Research 
-
CONFIDENTIAL Page 39 Final 
Amendment3 
16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 40 16June 20174. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately  120 subjects will be randomized to receive open- label study drug.  The target 
population is subjects with histologically  confirmed inoperable locally  advanced or metastatic 
adenocarcinoma of the stomach or the GEJ and who have received at least 1prior line of 
therap y. 
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study :
1)Age ≥18 years 
2)Histologicall y confirmed inoperable locally  advanced or metastatic adenocarcinoma of the 
stomach or GEJ which have progressed on at least 1prior sy stemic therapy or line of 
treatment for unresectable/ metastatic disease
3)Eastern Cooperative Oncology  Group (ECOG) ≤ 1
4)Measurable disease according to RECI ST v1.1
5)Tumor sites that can be accessed for repeat biopsies 
6) Archival tumor tissue, preferably obtained from the most recent available biopsy ; there must 
be adequate tissue for aPD-L1 stratification test, as assessed b y central pathologist
7)All toxicities attributed to prior anti- cancer therapy other than alopecia and fatigue must have 
resolved to grade 1 (NCI CTCAE version 4) or baseline
8)Subjects not receiving anticoagulant medication must have an international normalized ratio 
(INR) ≤ 1.5 and activated partial thromboplastin (aPTT) ≤ 1.5 x upper limit of normal 
(ULN) .The use of full -dose oral or parenteral anticoagulants is permitted as long as the INR 
or aPTT is within therapeutic limits (according to the medical standard in the institution) and 
the subject has been on stable dose of anticoagulants for at least 1 week at the time of 
randomization
9)Adequate h ematologic function
a)neutrophils ≥ 1.5 x 109/L
b)platelets ≥100 x 109/L
c)hemoglobin ≥9 g/dL
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 41 16June 201710) Adequate hepatic function
a)Direct or total bilirubin ≤1.5 x ULN
b)ALT and AST ≤2.5 x ULN
11)Creatinine clearance (CL cr)≥ 60 mL /min, estimated based on the Cockroft -Gault formula or 
measured based on 24 hour uri ne collection or other reliable method
12)For female subjects of childbearing potential, willingness to use a protocol -recommended 
method of contraception from the screening visit throughout the study  treatment period, for 
90days follo wing the last dose of andecaliximab andat least 5months after the last dose of 
nivolumab, unless the subject choose s continuous heterosexual abstinence as a lifest yle-
choice (seeAppendix 4for more information)
13)For male subjects of reproductive potential having intercourse with females of childbearing 
potential, willingness to use a protocol recommended method of contraception and to refrain 
from sperm donation from the start of study  drug, throughout the study  treatment period, and 
for 90 day s after administratio n of the last dose of andecaliximab ornivolumab 
(seeAppendix 4for more information )
14)Breastfeeding females must agree to discontinue nursing before stud y drug administration
15) In the judgment of the investigator, participation in the protocol offers an acceptable 
benefit -to-risk ratio when considering current disease status, medical condition, and the 
potential benefits and risks of alternative treatments for the subject’s cancer
16)Willingness to comply  with scheduled visits, dr ug administration plan, imaging studies, 
laboratory  tests, other study  procedures, and study restrictions
17)Evidence of a signed informed consent prior to implementation of any  protocol specific 
procedure
4.3. Exclusion Criteria
Subjects who meet any of the follo wing exclusion criteria are n ot to be enrolled in this study :
1)Subjects who have received only  neoadjuvant or adjuvant therapy  for gastric adenocarcinoma
2)Radiotherap y within 28 days of randomization; subjects given palliative radiotherap y to 
peripheral site s (eg, bone metastasis) may  enter the study  before 28 day s have elapsed 
provided the radiated sites do not contain lesions which may  be used to evaluate response, 
and must have recovered from an y acute, reversible effects
3)Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection, 
active gastrointestinal bleeding, uncontrolled cardiac arrhy thmia, or ps ychiatric illness/social 
situation that would limit compliance with study requirements as judged by treating 
physician
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 42 16June 20174) His tory of a concurrent or second malignancy  except for adequatel y treated local basal cell or 
squamous cell carcinoma of the skin; cervical carcinoma in situ; superficial bladder cancer; 
asymptomatic prostate cancer without known metastatic disease, with no requirement for 
therap y or requiring onl y hormonal therap y, and with normal prostate -specific antigen for 
≥ 1year prior to randomiz ation; adequately treated Stage 1 or 2 cancer currently  in complete 
remission; or any  other cancer that has been in complete remission for ≥ 5 y ears
5)Major surgery , defined as any  surgical procedure that involves general anesthesia and a 
significant incision (ie, larger than what is required for placement of central venous access, 
percutaneous feeding tube, or biopsy ), within 28 days of first dose of study  drug
6)Known positive status for human immunodeficiency  virus (HIV)
7) Known acute or chronic- active infection with hepatitis B virus (HBV) or hepatitis C virus 
(HCV)
8)Chronic daily  treatment with oral corticosteroids (dose of > 10 m g/day  prednisone 
equivalent) or other immunosuppressive medications within 14 day s of randomization . 
Inhaled steroids and short courses of oral steroids for anti
-emesis or as an appetite stimulant 
are allowed
9)Known or suspected central nervous s ystem metas tases
10)Known alcohol or drug abuse or an y other medical or psychiatric condition which 
contraindicates participation in the study
11)Documented my ocardial infarction or unstable/uncontrolled cardiac disease (ie, unstable 
angina, congestive heart failure [New York Heart Association > Class II ]) within 6 months of 
randomization
12) Serious sy stemic fungal, bacterial, viral, or other infection that is not controlled or requires 
intravenous 
antibiotics
13)Pregnant or breastfeeding women (pregnancy  needs to be excluded by  testing of beta-human 
chorionic gonadotropin [β-hCG])
14)Experimental medical treatment within 28 day s prior to randomization 
15)Known hypersensitivity to andecaliximab or nivolumab 
or excipients or to Chinese hamster 
ovary  cell products or to recombinant human or humanized antibodies
16)Prior treatment with anti -CTL A-4 agents (ipilimumab), anti -PD-1 or anti -PD-L1 agents 
(pembrolizumab, nivolumab), anti- PD-L2 agents, anti -MMP agents, or other 
immunomodulatory therapies
17)Previous severe h ypersensitivity  reaction to treatment with another monoclonal antibody  
therap y
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 43 16June 201718)Subject is expected to require an y other form of systemic or localized antine oplastic therap y 
while on study
19)Prior therap y with anti -tumor vaccines or other immuno -modulatory  antitumor agents
20)Current or history  of pneumonitis or interstitial lung disease
21) Active known or suspected autoimmune diseas e. Subjects with vitiligo, ty peI diabetes 
mellitus, residual hy pothy roidism requiring hormone replacement, or conditions not expected 
to recur in the absence of an external trigger are permitted to enroll
22)History  of bone marrow, stem cell, or allogen eic organ transplantation
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 44 16June 20175. INVESTIGA TIONAL  MEDI CINAL  PRODUCTS
5.1. Randomization
This is an open -label, randomized study .  Randomization to Arm A :  andecaliximab + nivolum ab 
or Arm B : nivolumab alone will be based on a randomization schedule prepared b y Gilead 
and/or a designee before the start of the stud y. Eligible subjects will be randomized via an 
interactive web response sy stem 
(IWRS).
The I WRS will be used to maintain a central log documenting screening, to implement 
randomization, to assess current inventories of study  drug, to initiate an y necessary  resuppl y of 
study  drug, and to document discontinuation of the study  drug. 
The I WRS will assign kit numbers and provide instructions for dispensing of study  drug 
(andecaliximab +nivolmab / n ivolumab alone ). It is anticipated that subjects will usually  begin 
study  drug immediatel y after randomization.
5.2. Description and Handling of Study Treatments
5.2.1. Formulation
5.2.1.1. A ndecaliximab
Andecaliximab is formulated as a sterile, aqueous buffered solution contain ingacetate at pH 5.0, 
with sucrose and pol ysorbate 20 added for stabilization. Each 10 mL vial contains 
400mg 
andecaliximab at a concentration of 40mg/mL.
5.2.1.2. Nivolumab
Nivolumab is commercially  sourced.  Information regarding the formulation can be found in the 
current prescribing information.
5.2.2. Packaging and Labeling
Study  drug andecaliximab (labeled as GS -5745) solution will be supplied in 10 mL  glass vials 
with coated elastomeric stoppers and aluminum crimp seals with flip- off caps.
Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), European Un
ion (EU ) guideline to Good Manufacturing Practice –Annex 13 
(investigational medicinal Product(s)), and/or other local requirements. Commercially  available 
product of nivolumab will be used for this study .
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 45 16June 20175.2.3. Storage and Handling
Andecaliximab should be stored at 2 to8 ºC. Storage conditions are specified on the study  drug 
label. Until dispensed to the subject, all study  drug s should be stored in a securel y locked area, 
accessible only  to authorized site personnel. To ensure stability  and proper identification, the 
study  drug should be stored in the containers and packaging in which they  were supplied until 
dosing to the subject.
Comme rcial nivolumab will be used for the stud y. Further information regarding preparation ,
storage ,and handling are available in the Prescribing Information or SmPC for nivolumab.
Information regarding prepar ing andecaliximab IV infusion scanbe found in the pharmacy  
manual. 
5.3. Dosage and Administration of Study Drug
For Arm A, andecaliximab will be admi nistered 800 mg via IVinfusion over approximately  
30(±5) minutes at the research clinic b y a qualified staff member on Day  1and every  2weeks 
thereafter .Following administration of andecaliximab, nivolumab will be administered 3 mg/kg 
via IV infusion over approx imately  60 (± 5) minutes on Day  1and every  2 weeks thereafter.
For Arm B, nivolumab will be administered 3mg/kg via IV infusi on over approximately  
60(±5)minutes on Day  1and every  2 weeks thereafter.
The Investigator or a qualified designee must be present during administration. Subjects should 
be observed following end of infusion and discharged at the discretion of the Investigator or 
qualified designee .
5.3.1. Dose Adjustments
If an AEis attributed to only  1 drug ( andecaliximab or nivolumab ), the investigator’s discretion 
will be used to determine if the drug not attributed to the adverse event will be withheld based on 
the investigator’s assessment of risk- benefit of withholding 1 or both drugs.
5.3.1.1. A ndecaliximab
If a subject experiences a Grade 3 toxicity  or greater that i s felt to be due to study  drug 
andecaliximab ,treatment will be postponed until the toxicity  is resolved to Grade 0 or1 
(asdefined b y CTCAE v4.03) or returns to the subject’s baseline value. If the toxicity  is 
resolved to 
Grade 0 or 1 or returns to the sub ject’s baseline value , the subject may  resume 
andecaliximab at 
the originally assigned dose level. I f the subject experiences a recurrence of the 
Grade 3 or greater toxicity after restarting andecaliximab , treatment with andecaliximab will be 
discontinued.
5.3.1.2. Nivolumab
Please refer to the current nivolumab label or SmPC for y our respective region for recommended 
dose modification guidelines and full discontinuation criteria with nivolumab.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 46 16June 20175.4. Prior and Concomitant Medications
At Screening, all medication taken up to 30 day s prior to the screening visit will be recorded on 
the eCRF. At each study  visit, the site will capture any  and all medications taken by  the subject 
since the last visit or during the visit (as applicable). Conco mitant medications include 
prescription and non -prescription medications, pre -infusion medicat ions (eg, anti -emetics), and 
vitamins and minerals. 
In addition, supportive therapies given during the course of the stud y (eg, blood transfusion, 
growth factor) willbe collected and recorded on the eCRF. 
During the course of the clinical trial, study  subjects are anticipated to continue the use of 
prescribed medications identified during the screening procedures, consistent with study  
inclusion and exclusion cr iteria. 
Non-study  anticancer chemotherapy  or immunotherapy  (approved or investigational) isnot 
permitted during the trial. If administered, the subject may  be removed from the trial.
Inhaled steroids and short courses of oral steroids for anti
-emesis or as an appetite stimulant are 
allowed; however, chronic daily  treatment with oral corticosteroi ds (dose of ˃ 10 mg/day 
prednisone equivalent) are not. 
5.4.1. Acceptable Concomitant Medications
All treatments that the investigator considers necessary  for a subject ’s welfare may  be 
administered at the discretion of the investigator in keeping with the community  standards of 
medical care.  All concomitant medication will be recorded on the case report form (CRF) 
including all prescription, over -the-counter (OTC), her bal supplements, and IV medications and 
fluids.  I f changes occur during the trial period, documentation of drug dosage, frequency , route, 
and date may  also be included on the CRF.
All concomitant medications received within 30 days before the first dose o f trial treatment and 
30 day s after the last dose of trial treatment should be recorded. 
5.4.2. Prohibited Concomitant Medications
Subjects are prohibited from receiving the following therapies during the Screening and 
Treatment Phase (including retreatment for post-complete response relapse) of this trial:
Antineoplastic c hemotherapy  or biological therapy  not specified in the protocol
Immunotherap y not specified in this protocol
Investigational agents other than those specified by  the protocol
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 47 16June 2017Radiation therap y 
Note:  Radiation therap y to a sy mptomatic solitary lesion or to the brain may  be 
considered on an exceptional case -by-case basis after consultation with theSponsor.  The 
subject must have clear measurable disease outside the radiated field.  Administrati on of 
palliative radiation therapy  will be considered clinical progression for the purposes of 
determining PFS.
Live vaccines within 30 day s prior to the first dose of trial treatment and while participating 
in the trial.  Examples of live vaccines include , but are not limited to, the following: measles, 
mumps, rubella, chicken pox, y ellow fever, rabies, BCG, and t yphoid (oral) vaccine. 
Seasonal influenza vaccines for injection are generally  killed virus vaccines and are allowed. 
However, i ntranasal influen za vaccines (eg, Flu - Mist®) are live attenuated vaccines, and 
are not allowed.
Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of 
suspected immunologic etiology .  The use of ph ysiologic doses of corticosteroids may  be 
approved after consultation with the Sponsor.
Note:  I nhaled steroids are allowed for management of asthma.
Subjects who, in the assessment by  the investigator, require the use of any  of the aforementioned 
treatments for clinical management should be re
moved from the trial.  Subjects may  receive 
other medications that the investigator deems to be medicall y necessary.
The Exclusion Criteria describes other medications that are prohibited in this trial.
There are no prohibited therapies during the Post -Treatment Follow -up Phase.
5.5. Accountability forStudy Drug
The investigator or designee (eg, pharmacist) is responsible for ensuring adequate accountability  
of all used and unused investigational medicinal product during the study . This includes 
acknowledgement of receipt of each shipment of study  drug (quantity  and condition) and 
tracking of vials assigned/utilized for subject dosing.
Study  drug ( andecaliximab and or nivolumab )accountability  records will be provi ded to each 
study  site to:
Record the date r eceived and quantity  of study  drug vials
Record the date, subject number, subject initials, the vial number dispensed
Record the date, quantity of used and unused vials returned, along with the initials of the 
person recording the information.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 48 16June 2017Dispensing records will include the initials of the person dispensing the study  drug or supplies. 
5.5.1. Study Drug Return or Disposal
The study  drug s (andecaliximab and nivolumab )should be disposed of at the site as per local 
standard operating procedures. Please see pharmacy  binder for additional instructions (See 
Section 9.1.7 for details
). 
Andecaliximab (fo1medy GS-5745 ) 
Protocol GS-US-296 -2013 
Gilead Sciences, Inc. 
6_ STUDY PROCEDURES Final 
Amendment3 
The study proced ures to be conducted for each subject enrolled in the study are pr esented in 
tabular fonn in Appendix 2 and descr ibed in the text that follows. 
The investigato r must docume nt any deviatio n from protocol procedures and n otify the sponsor 
or contract research organizatio n (CRO). 
Safety and tolerability assess ments will include regular monitoring of AEs, changes from 
baseline in laborato1y variables, physical examinatio ns, vital signs, and speci al safety 
assess ments such as ECGs. 
From the time of obtain ing infonned consent through the first admini stration of study diug, 
record all SAEs , as well as any non-serious AEs related to protocol -mandated proced ures on the 
AEs eCRF. All other untoward medica l occmTe nces observe d dming the Scree ning period, 
including exace rbatio n or changes in medical histo1y are to be captured on the medical histo1 y 
eCRF. 
6.1. Subject Enrollment and Treatment Assignment 
Subject eligib ility will be estab lished at the conclusion of the screening evaluations. The 
scree ning numbe r and/o r subject ID will be assigned for that individual subject by the designated 
IWRS. Subject eligibility must be detennined by results received from the central lab as 
described in Sectio ns 6.2.2 and 6.2.8 . 
It is the respo nsibility of the investigator to ensme that each subject is eligible for the study 
before randoinization. A su bject will be considered e nrolled once he or she has completed 
randoinizat ion. 
Subjects will undergo proced ures defined in Appendix 2. Detai ls regarding randomizatio n and 
treatment assignment are in Section 5 .1. 
6.2. Study Procedure Description s 
The following sections describe the individu al study procedmes outlined in subseq uent sectio ns 
and the sched ule of assessments. During the treatme nt period, all visits may be perfo1med within 
the w indows identified in Appendix 2. 
6.2.1. Informed Consent 
All subjects must sign and date the most recent IRB/I EC-appro ved infonned consent f01m befo re 
any study specific proced ures are erfonned exce t where n oted in the rotocol in relatio n to 
standa rd of care roced mes. 
CONFIDENTIAL Page49 16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 50 16June 20176.2.2. Re-Screening Criteria
Subjects who do not randomize within 28 day s of screening will be screen failed. 
Re-screening may  be allowed. Subjects who are re -screened after 28 days must be re -consented 
with a new screening number and the screening assessments must be repeated. F or subjects that 
are re-screened within 28 days, assessments with results that would ex clude the subject will need 
to be repeated.
Subject eligibility must be determined b y results received from the central lab. How ever, if there 
has been at least 1 failed attempt to obtain test results from the central lab, eligibility  may  be 
determined usi ng local lab results, with documentation of failed attempts, local lab results, and 
sponsor approval .
6.2.3. Medical & Medication History
A complete medical and surgical history  will be obtained by  the investigator or designee at 
screening , including disease hist ory, and recorded on the eCRF.
All medications taken within 30 day s prior to screening and during the screening period will be 
obtained prior to randomization and recorded on the eCRF. At each stud y visit, the site will 
capture any and all medications take n by the subject since the last visit or during the visit 
(asapplicable). Concomitant medications include prescription and non -prescription medications, 
vitamins and minerals. 
In addition, supportive therapies given during the course of the stud y (eg, bl ood transfusion, 
growth factor) should be collected and recorded on the eCRF.
6.2.4. Physical Examination
A phy sical examination (PE) will be performed at screening, end of treatment (EOT), and EOS . 
This will include assessment of clinical signs and sy mptoms. The exam will be performed b y a 
physician, a phy sician’s assistant, or nurse practitioner qualified to perform assessments. Breast, 
genital, and rectal examinations are not required, unless war ranted in opinion of the healthcare 
provider. 
A modified phy sical exam capturing changes from prior exams will be performed on Day 1and
every  4 weeks thereafter, and at the 30- day Safet y Follow -up. Height will be collected at 
Screening 
only.
6.2.5. Vital Signs & Weight
Vital signs including blood pressure, heart rate, respiratory  rate,and oral temperature will be 
measured b y the investigator or qualified designee as per standard institutional guidelines at each 
study  visit as indicated in Appendix 2. Weight wi ll be collected at the same visits vital signs are 
taken.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 51 16June 20176.2.6. Electrocardiogram Assessment
A single 12 -lead electrocardiogram (ECG) will be collected at S creening, Day  1, and every  
4weeks thereafter at subsequent visits, andat the EOT and EO Svisits ,as indicated in 
Appendix 2. The investigator will review all ECGs and retain the tracing with the source 
documents.
6.2.7.
Performance Status
Performance status will be scored using the ECOG performance status scale index 
(refer toAppendix 3), at Screening, Day 1and every 4 weeks thereafter , EOT, EOS ,and 30- day 
Safety  Follow -up visits. ECOG used to determine eligibility  must be the performance status 
during the screening period. ECOG performance status on Day  1may be waived if it was 
conducted 
during screening within 4 day s ofDay 1. 
6.2.8. Laboratory Assessments
The central laboratory  will be responsible for chemistry , hematology , coagulation, urinaly sis, 
and serum pregnancy  testing (per Table 6-1) as well as processing and/or storage of other study  
samples. Specific instructions for processing, labeling, and shipping samples will be provided in 
a central laboratory  manual. The date and time of sample collection will be reported to the 
central laboratory .
If central laboratory  results are not available, local laborat ories may  be used for dosing decisions. 
Local laboratory  assessments resulting in a dose change or as part of an AEassessment , which is 
not supported by  central lab results, will be reported on the eCRF.
Urine pregnancy  test will be performed locall yat 
the site. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 52 16June 2017Table 6-1. Analytes
Chemistry Urinalysis Hem atology Other 
Albumin
Alkaline phosphatase
ALT 
AST 
Bicarbonate
BUN
Calcium
Chloride
Creatininea
Glucose
Lipase
Amylase
Magnesium
Phosphorus
Potassium
Sodium
Total bilirubin
Direct bilirubin
Total protein
CEA
CA125Color and appearance
Specific gravity
pH
Occult blood
Protein
Glucose
Bilirubin
Leukocyte esterase
Nitrite
Urobilinogen
Ketones
Microscopicb\WBC
Hem oglobin
Hem atocrit
Platelet
ANC
Differential
Eosinophil s
Lymphocyte s
Monocyte s
Neutrophil sSerum β-hCG or urine 
pregnancy testc
Thyroid Function Tests (TSH, 
T3, freeT4)d
Coagulation
PT/INR
aPTT
ANC = absolute neutrophil count; ALT = alanine aminotransferase; aPTT = Activated Partial Thromboplastin Time ; 
AST =aspartate ami notransferase; BUN =blood urea nitrogen; CEA=carcinoembryonic antigen; β-hCG = beta -human
chorionic gonadotropin; INR = International Normalized Ratio ; PT =Prothrombin Time; WBC = white blood cell ; 
CA125=Carbohy drate Antigen 125 ; TSH = thyroid stimulating hormone; T3 = triiodothyronine; Free T4 = free thyroxine
a Estimated creatinine clearance (CL cr)/glomerular filtration rate will be calculated based on the Cockroft -Gault formula using 
actual body weight: CL cr(mL/min) = (140 – age [years])*  weight (kg) / (serum creatinine [mg/dL] *72).  If the subject is 
female, m ultiply the quantity by 0.85 .
b Reflex testing based on other abnormalities
c Females of child -bearing potential only. Serum pregnancy will be conducte d at Screening. Urine pregnancy will be 
conducted pre -dose on Day 1 ,every 4 weeks thereafter , at EOT, and EOS, 30-day, and 5 - month Safety Follow -up
d TSH, T3, and free T4 will be tested by the central laboratory at screening. From Week 8 and beyond, T3 an d T4 will be 
tested reflexively based on abnormal TSH results.
Screening laboratory samples should be obtained within 28 days prior to randomization. Blood 
samples will be obtained for hematology , chemistry , coagulation, thyroid function, and 
pregnancy  testing for female subjects. A urine sample will also be obtained at screening for 
urinaly sis.
Blood samples for hematology  and chemistry  will be obtained at pre -dose on Day 1and every  
2weeks thereafter , EOT, EOS, 30- day,and 5 -month Safety  Follow -up. Blood samples for 
Thyroid Function Tests (TSH, T3, free T4) will be collected every  8 weeks, and at EOT, EOS, 
30-day, and 5 -month Safety  Follow -up. A urine sample for urinal ysis and pregnancy  testing for 
female subjects will also be obtained on Day 1and every  4weeks 
thereafter , EOT, EOS, 30- day,
and 5 -month Safet y Follow -up. Blood samples for coagulation will be obtained at EOT and EOS.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 53 16June 2017At any  time during the study , abnormal laboratory parameters that are clinically  relevant 
(eg,lead to clinical s ymptoms or signs, require therapeutic intervention), and constitute an AE 
must be recorded in the eCRF.
6.2.8.1. Pregnancy  Test
All females of childbearing potential (see Appendix 4) will have a serum pregnancy test at 
screening. Urine pregnancy  tests will be perfo
rmed every  4 weeks starting on Day  1, EOT, EOS, 
30-day,and 5 -month Safety  Follow - up.
6.2.8.2. Pretreatment, On- treatment and Progression B iopsies
If biopsies are endoscopic gastric ,at least 4 biopsies at each time -point (pre -treatment, 
on-treatment , and at progression) should be obtained. If biopsies are from other sites, core 
needle biopsies, excisional, resections, incisional, or punch biopsies are acceptable. For core 
needle biopsies, at least 3 cores should be collected. Refer to the laboratory m anual for tissue 
processing instructions. It is preferred that on treatment and progression biopsies be taken 
from primary  (gastric or GEJ tissue) lesions and/or the same site as the pre -treatment (or
archival )tissue.  If tissue is not available or acces sible from the primary  lesion (gastric or 
GEJ tissue), biopsies of metastatic lesions are acceptable.  Pre-treatment: To be obtained
within the screening window or an ytime after last line of therapy ; The pretreatment biopsy  is
requested if archival tumor sample provided to meet I nclusion Criterion #6 is from before the 
last line of therap y
On-treatment: To be obtained any time within the window of 
Week 5 through Week 9
At progression: To be obtained at disease progression (if medicall y feasible)
6.2.8.3.
Anti-A ndeca liximab Antibody
For Arm A onl y, blood samples for anti -andecaliximab antibody  will be collected prio r to dosing 
atthe following visits: Day 1, Week s 4, 8, 16, 24, and every  3 months thereafter, and at the EOT 
and EOS visits. 
6.2.8.4. A ndecaliximab Pharmacokinetics
For Arm A onl y, blood plasma samples will be collected for andecaliximab PK at 30 (± 
15)minutes after the end of infusion on Day  1,prior to dosing, and 30 (± 15) minu tes after the 
end of infusion at Week s 4, 8, 16, 24, and every  3 month sthereafter, and at the EOT and EOS 
visits. 
Andeca liximab (fo1medy GS-5745) 
Protoco l GS-US-296-2013 
Gilead Sciences , Inc. 
6.2.8.5. Biomarkers Final 
Amendment3 
Sample s for biomarker analysis as listed in Table 3-1 will be collected as follows and in 
Appendix 2: 
• Blood biomarker sampl es will be collected at screening, prior to dosing on D ay 1, Weeks 2, 
4, 8, 16, 24, and eve1 y 3 months there after, and at EOS or at disease progression. 
• An oral sample (saliva or other) for characterization of oral microbiome diversity will be 
collected prior to dosing on D ay 1. 
I 
6.2.9. 
6.2.9 .1. Disease and Response Assess ment 
Efficacy Measurement 
RECIST version 1.1 {Eisenhauer 2009 } [ Appendix 5] will be used for assess ment of tumor 
responses for the purp oses of study evaluation, managing patients on protoco l treatmen t, and 
decision makin g for discontinuation of study therapy due to disease progression, w ith some 
modifications to account for atypical responses which m ay occur with immun e-based therapies 
{ Swaika 2015 }. Given that anti PD-1 agents produce anti tumor effects by potentiatin g 
endoge nous cance r-specific immun e respon ses, the respo nse patterns seen with t hese agents may 
extend beyond the typical time course of responses seen with cytotox ic ag ents. In addition, 
anti-PD-I therapies can occasiona lly ma nifest a clinical respon se after an initial increase in 
tumor burden or even the appea rance of new lesions ("tumor flare" or "p seudoprogression") 
{Topalian 2014 }. In these cases , standard RECIST m ay not prov ide an accurate response 
assess ment of anti PD-1 agents. 
Therefore, RECIST 1.1 w ill be used [Appendix 5] with the following adaptations: 
If imaging shows a CR or PR, tumor imaging sho uld be repe ated at least 4 weeks (~4 weeks) 
later to confnm response, per RECIST 1.1 g uidelines. Subjects will then re turn to regular 
scheduled imaging eve1 y 8 weeks staiiing with the n ext protocol- specified imaging time-point. 
Subjects who ob tain a confnmat o1 y scan do not need to undergo scheduled imaging assess ment 
:S2 weeks later (eg, if a subj ect obtains a scan at Week 22 to confnm a Wee k 16 r espo nse, they 
will not al so be re quired to complete the scheduled Wee k 24 scan). 
If imaging shows progressive disease (PD), it is at the discretion of the investigator to k eep the 
subject on s tudy treatment or to stop study treatment until imaging is rep eated ~4 weeks later in 
order to confnm PD (adapted from the immun e-related response criteria recommendations) 
{Wolchok 2009 }. Patients that are deemed clinically unstable or who h ave biopsy-proven new 
metastatic lesions are n ot required to have rep eat imaging for confmn ation. The decision to 
continue a su bject on study while awaiting PD confnmati on w ill be ba sed on clinical judgment 
of a s ubject's overa ll clinical condition, including per fonnan ce status, c linical symptoms, and 
laborato1 y data. 
CONF IDENTIAL Page 54 16 June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 55 16June 2017At a minimum, subjects must meet the following criteria for continued treatment on study  after 
disease progression is identified at a tumor assessment:
Absence of signs and s ymptoms (including worsening laboratory values) indicating disease 
progression
No decline in ECOG performance status
Absence of rapid progression of disease or of progressive disease at critical ana tomical sites 
(eg,cord compression) requiring urgent alternative medical intervention
Study  treatment may  continue under the following circumstances after repeat/confirmatory  
imaging ( ≥4 weeks after initial scan showing PD):
If repeat imaging shows < 20% tumor burden increase compared to nadir, stable or improved 
previous new lesion (if identified as cause for initial PD), and stable/improved non- target 
disease (if identified as cause for initial PD), treatment may  be continued and/orresumed
(PD is not confirmed) .  
If repeat imaging confirms PD due to any  of the scenarios list edbelow, subjects will be 
discontinued from study  therap ywith the following exception : if the subject is achieving a 
clinically  meaningful benefit, and there is no further increase in the tumor burden at the 
confirmatory  tumor imaging compared to the initial PD assessment, an exception to continue 
treatm ent may  be considered following consultation with the Sponsor. In this case, if 
treatment is continued, tumor imaging s hould continue to be performed at the protocol 
specified intervals.
In determining whether or not the tumor burden has increased or decr eased, site study  team 
should consider all target lesions as well as non -target lesions.
If repeat imaging shows an objective response or stable disease relative to nadir, treatment with 
study medication may  continue and subject s will return to regular sch eduled imaging every  
8weeks starting with the next protocol -specified imaging time-point .  Subjects who obtain a 
confirmatory  scan do not need to undergo scheduled imagi ng assessment 
≤2 weeks later (eg, if a 
subject obtains a scan at Week 14 to confirm a Week 8 PD and progression is not confirmed, 
they will not also be required to complete the scheduled Week 16 scan).  
Progressive Disease is confirmed at repeat imaging if:
Tumor burden remains ≥ 20% ( and at least 5 mm absolute increase )compared to nadir
Non-target disease resulting in initial PD is worse (qualitative)
New lesion(s) resulting in initial PD is worse (qualitative)
Additional new lesion(s) since last evaluation
If repeat imaging confirms PD, subject s will be discontinued from study therapy .
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 56 16June 2017Table 6-2. Imaging and Treatment after F irst Radiologic E vidence of 
Progressive Disease 
Clinically Stable Clinically Unstable
Imaging Treatm ent Imaging Treatm ent
First radiologic 
evidence of PD 
by RECIST 1.1 Repeat imaging at 
>4 weeks at site 
to confirm PDMay continue study 
treatment at the local 
site Investigator’s 
discretion while 
awaiting 
confirmatory tumor 
imaging by site by 
irRECIST.Repeat imaging at >
4 weeks to confirm 
PD per physician 
discretion onlyDiscontinue treatment
Repeat tumor 
imaging confirms 
PD by RECIST
(see modifications 
in protocol)No additional 
imaging requiredDiscontinue 
treatment (exception 
is possible upon 
consultation with 
sponsor)No additional 
imaging requiredN/A
Repeat tumor
imaging shows 
SD, PR ,or CR by 
RECIST (see 
protocol for 
details)Continue 
regularly 
scheduled 
imaging 
assessmentsContinue study 
treatment at the local 
site Investigator’s 
discretionContinue regularly 
scheduled imaging 
assessmentsMay restart study 
treatment if condition has 
improved and/or clinically 
stable per Investigator’s 
discretion. Next tumor 
image should occur 
according to the every 
8week imaging schedule
In subject s who discontinue study  therapy earl y without documented disease progression, every 
effort should be made to continue monitoring their disease status by  radiologic imaging 
following guideli nes for end of study  follow -up (Section 6.2.9.2).
When feasible, subjects should not be discontinued until progression is confirmed ; investigators 
should discuss with the Gilead Medical Monitor prior to subject discontinuation .  
6.2.9.2. Tumor I maging 
Contrast -enhanced CT(without contrast if use of contrast is contraindicated)
orgadolinium -
enhanced MRI of the chest, abdomen, and pelvis will be performed at screening, every  8weeks 
during the stud y and at the EOS visit if one has not b een performed within the last 8 weeks. CT 
is the preferred imaging modality  for this study .Tumor burden will be evaluated solel y based on 
radiographic imaging per RECI ST v 1.1, with the modific ations noted in S ection 6.2.9.1. Chest 
x
-ray, ultrasound, endoscopy , laparoscop y, positron- emission tomograph y, radionuclide scans, or 
tumor markers will not be considered for respon se assessment.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 57 16June 2017For radiographic evaluations, it is recommended that the same method of assessment and the 
same technique (eg, scan type, scanner, subject position, dose of contrast , injection/scan interval) 
should be used to characterize each identified an d reported lesion at baseline and during study  
treatment and follow -up.Local site study  team reading (investigator assessment with site 
radiology  reading) based on RECI ST 1.1 will be used to determine subject eligibility .
Scans taken as part of standard medical practice up to 28 days prior to randomization can be used 
for Screening as long as they  are of diagnostic quality  and meet all study  requirements. During 
the treatment phase, scans may  be performed at time points oth er than every 8 weeks as 
clinically  indicated to assess tumor progression. 
For subjects who stop study  treatment in the absence of disease progression (eg, experienced 
unexpected toxicity ), scans should continue to be collected approximately  every  8 weeks until 
disease progression or initiation of sy stemic anti -tumor therapy  other than the study  treatment, 
whichever is earlier. 
All relevant clinical and radiographic information required to make each assessment must be 
made available for source verification and submission to a central reader.  
Disease progression 
will be determined b y the investigator or qualified designee.
Imaging should be continued at protocol- specified intervals until whichever of the following 
occurs first: 
Initial site -assessed disease progression is confirmed
The start of new anti -cancer treatment
Withdrawal of consent
Death 
The end of the stud y
6.2.10. Study Drug Administration 
For Arm A, andecaliximab will be administered via IV infus ion over approximately  30 (± 
5)minutes on Day  1and every  2 weeks thereafter . Following andecaliximab dosing, subjects 
will also be administered nivolumab via I V infusi on over approximately  60(± 5) minutes. 
For Arm B, nivolumab will be administered via IV infusion over approximately  
60(±5)minutes.  
Study  drug dosing must be documented on the eCRF.
CCI
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 58 16June 20176.2.11. Adverse Events
From the time of obtaining informed consent through the first administration of study  drug, 
record all SAEs as well as any AEs related to protocol -mandated procedures on the AE eCRF.
All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical h istory  eCRF.
From the time of the first administration of study  drug through 30 day s post the l ast 
administration of andecaliximab and 5 months post -treatment of nivolumab , record an y SAEs, 
and AEs including exacerbation or changes in medical history , on t he AE eCRF.
See Section 7Adverse Events and Toxicity  Management for additional details.
6.3. Assessments for Premature Discontinuation from Study
If a subject has discontinued all study  treatments prior to definitive disease progression, the 
subject shall rema in on study  for follow -up for progression -free survival (see Sections 3.5and 
3.6). Every  attempt should be made to keep the subject in the stud y and continue to perform 
tumor evaluation by  CT or MRI  every  8 weeks. Subjects will remain on study  until disease 
progression or initiation of non -study  specific anti -neoplastic therap y in the absence of 
progression, whichever occurs earlier.
If it is not possible 
to keep the subject on study , or acceptable to the subject or investigator, the 
subject may  be w ithdrawn. I t is recommended that the investigator consults with the medical 
monitor prior to removing the subject from stud y for an y reason except subject withdrawal of 
consent.
6.4. Criteria for Discontinuation of Study Treatment
See Section 3.5for discontinu
ation criteria.
6.5. End of Treatment
End of treatment (EOT) assessments will be completed only  by subjects who discontinue all 
treatment for reasons other than progressive disease, initiation of new anti-neoplastic therap y,or 
full withdrawal of consent .  These assessments should be completed as soon as possible after the 
decision is made. Every  attempt should be made to keep the subject in the study and continue to 
perform tumor evaluation by  CTor MRI every  8 weeks until disease progression.   
6.6. End of Study
End of study  (EOS) assessments will be completed 
when the subject meets at least 1 of the 
criteria for study  discontinuation (Section 3.7).
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 59 16June 20176.7. 30- Day Safety Follow -Up
A Safet y Follow -up visit will be performed 30 days ( 7 day s) fol lowing the last dose of 
andecaliximab . The 30- day Safet y Follow -up visit may  be substituted by  a scheduled study  visit 
if it occurs within the same window.
6.8. 5- Month Safety Follow -Up
A Safet y
Follow -up visit will be performed 5 months ( 7 day s) fol lowing th e last dose of 
nivolumab. The 5-Month Safety Follow -up visit may  be substituted by  a scheduled study  visit if 
it occurs within the same window.
6.9. Long -Term Follow -
Up
Long term follow -up for OSbegins once a subject discontinues study  for reasons other than 
death . Subjects will be contacted via phone call every  3months for determination of long -term 
survival status and record
ingof any  other anti -cancer therap yand cancer related surgery  after the 
EOS visit. 
Subjects who are not deceased b
y the time Gilead h as made the determination the study  will be 
ended will receive a final follow -up phone call to assess survival status and communicate the 
Sponsor’s decision. 
The investigator will make every effort to contact the subject or a close relative or caretaker b y 
phone to collect survival information. The investigator should show due diligence b y 
documenting in the source documents steps taken to contact the subject (ie, dates of phone calls, 
registered letters, etc).
6.10. Unscheduled visits
Unscheduled visits may  occur at any  time while the subject is enrolled on study .Data generated 
during an unscheduled visit will be collected on the eCRF.
6.11. Protocol Deviations
Gilead’s policy  prohibits exemptions from protocol inclusion/exclusion criteria. In the event of a 
significant deviation related to gross non -compliance from the protocol or incidences that impose 
significant risk to subject safet y, the investigator or designee must notify Gilead and/or its 
designee immediatel y. The site will be requir ed to document deviations in accordance with 
Gilead’s procedures and in accordance with the site’s procedures and processes.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 60 16June 20177. ADVERSE EVENTS AND T OXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An AE is an y untoward medical occurrence in a clinical study subject administered a medicinal 
product, which does not necessarily  have a causal relationship with the treatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or dise ase temporally  associated 
with the use of a medicinal product, whether or not considered re lated to the medicinal product. 
AEs may  also include pre -or post -treatment complications that occur as a result of protocol 
specified procedures, overdose ,drug abuse/misuse reports , or occupational exposure . Preexisting 
events that increase in severity or change in nature during or as a consequence of participation in 
the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (eg ,hospitalization for 
chemotherap y infusion per institutional guidelines, elective surgery , social and/or 
convenience admissions)
Overdose without clinical sequelae 
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
AnSAE is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 61 16June 2017In-patient hospitalization or prolongation of existing hospitalization (Note: H ospitaliza tion 
for chemotherap y infusion or other ‘social hospitalization’ per institutional guidelines will 
not be considered an SAE.)
Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medicall y important event or reaction: such ev ents may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to deter mine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  important e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a 
medicall y important e vent and subject to expedited reporting 
requirements.
7.1.2.1. Protocol -Specific Serious Adverse Event Instructions
To maintain the integrit y of the study , disease progression and death from disease progression 
should be reported as SAEs by  the investigator only ifit is assessed that the study  drugs caused 
or contributed to the disease progression (ie, by  a means other than lack of effect). Unrelated 
disease progression should be captured on the eCRF.
In addition, events that are indicative of the following disease -related SAEs that are assessed as 
unrelated to stud y drugs will not be reported as expedited reports b y Gilead during the stud y:
Progression of gastric adenocarcinoma
Death related to disease progression
These events will be exempt from global expedited reporting requirements for the duration of t he 
study  as they  are key endpoints of this study . They will be reported as appropriate in the final 
clinical study  report as well as any  relevant aggregate safety  report.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interr uption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 62 16June 2017definition of an AE or SAE as described in Sections 7.1.1 and7.1.2. If the laboratory  
abnormality
 is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (eg, decreased hem oglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.6.
7.2. Assessment of Adverse Events and Serious Adverse Events
The i
nvestigator or qualified subinvestigator is responsible for assessi ng AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for asse ssing t he relationship to study  
drug using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the study  drug. For 
SAEs, an alternative causality  must be provided (eg, pre -existing condi tion, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  procedure.
Yes: The adverse event occurred as a result of protocol procedures, (eg., venipun cture)
7.2.2. Assessment of Severity
The severit y of AEs will be graded using the Common Terminology  Criteria for Adverse Events 
(CTCAE), Version 4.03 in the study  manual.
If a CTCAE term is not available for the AE/SAE, the severit y will be graded using 
Grade 1through Grade 5 as defined in the CTCAE definiti ons.
The distinction between the seriousness and the severity  of an AE should be noted. Severe is a 
measure of intensit y; thus, a severe (Grade 3) reaction is not necessarily  a serious reaction. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 63 16June 20177.3. Investigator Requirements and Instructions for Reporting Ad verse Events 
and Serious Adverse Events to Gilead
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF: 
All SAEs and adverse events related to protocol -mandated procedures
7.3.1. Advers e Events
Following initiation of study  medication , collect all AEs, regardless of cause or relationship, 
until 30 day s after last administration of study  drug andecaliximab and 5 months post -treatment 
of nivolumab, must be reported to the eCRF database as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow
-up 
period.
7.3.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and Gilead DSPH as instructed. This also includes any SAEs resulting from 
protocol -associated procedures performed after informed consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 days of the 
last dose of study  drug andecaliximab and 5 months post -treatment of nivolumab , regardless of 
causality , should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period ; 
however, if the investigator learns of any  SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of study drug, he/she should promptly  document and 
report the event to Gilead DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline
.
SAEs will be reported using an electronic SAE (eSAE) sy stem . 
7.3.2.1. Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database a nd from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
Andecaliximab (fo1medy GS-5745 ) 
Protoco l GS-US-296 -2013 
Gilead Sciences , Inc. Final 
Amendment3 
• If for any reaso n it is not possib le to record the SAE infonnation electro nically (ie, the eCRF 
database is not functioning) record the SAE on the pape r serious adverse event repo1t ing 
fo1m and submit within 24 hours to: 
Gilead DSPH: Fax: 
Emai l: 
• As soon as it is possi ble to do so, any SAE repo1ted via paper must be transcr ibed into the 
eCRF database acco rding to instruct ions in the eCRF completion guidelines. 
• If an SAE has been repo1ted via a paper fonn because the eCRF database has been locked, no 
fuither action is necessa 1y. 
• For fatal or life-threatening events, copies of hospital case repo1ts, autopsy repo1ts, and other 
documents are al so to be submitted by e-mail or fax when r equested and applicab le. 
Transmissio n of such docume nts shou ld occur without personal subject identification , 
maintain ing the ti·aceabi lity of a docume nt to the su bject identifiers . 
• Additio nal infonnation may be requested to ensure the timely comp letion of accurate safety 
repo1ts. 
• Any medications necessaiy for ti·eatine nt of the SAE must be recorded onto the concomita nt 
medicat ion section of the su bject's eCRF and the event description section of the SAE fonn. 
7.4. Gilead Reportin g Requirem ents 
Depe nding on rel evant local legislatio n or r egulations, including the applicab le US FDA 
Code of Federal Regu lations, the EU Clinical Trials Directive (2001/20/EC) and relevant 
updates, and other countiy -spec ific legislatio n or r egulations, Gilead may be required to exped ite 
to worldwide regulato1y agencies repo1ts of SAEs , SAD Rs, or suspected unexpected serious 
adverse reactio ns (SUSARs). In accordance with the EU Clinical Trials Direct ive (2001/20/EC), 
Gilead or a spec ified designee will notify worldwide regulato1 y agencies and the relevant IEC in 
concerned Member States of applicable SUSARs as outlined in cmTent regulations. 
Assessme nt of expectedness for SAEs will be dete1mined by Gilead using reference safety 
info1matio n spec ified in the IB or relevant local label as applicable. 
All investigators will receive a safety letter notify ing them of relevant SUSAR repo1ts associated 
with any study dmg. The invest igator shou ld notify the IRB/IEC of SUSAR repo1ts as soon as is 
pract ical, where this is required by local regulato1y agencies, and in acco rdance with the local 
institutio nal policy. 
7.5. Clinical Laborator y Abnormalitie s and Other Abnormal Assess ment s as 
Adverse Events or Seriou s Adv erse Events 
Seve rity shou ld be recorded and graded acco rding to the CTCAE (version 4.03). 
CONFIDENTIAL Page 64 16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 65 16June 2017For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
7.6. Toxicity Management
Treatment -emergent toxicities will be noted by  the Investigator and brought to the attent ion of 
the Gilead Sciences Medical Monitor or designee . Whet her or not considered treatment -related, 
all subjects experiencing AEs must be monitored periodicall y until symptoms subside, any 
abnormal laboratory  values have resolved or returned to baseline l evels or they  are considered 
irreversible, or until there is a satisfactory explanation for the changes observed.
Grade 3 or 4 clinicall y significant laboratory abnormalities should be confirmed by repeat testing 
as soon as practical to do so, and preferab ly within 3 calendar day s after receipt of the original 
test results. Laboratory abnormalities (eg, thiamine deficiency ) identified at screening/baseline 
and during study  participation should be treated at the investigators discretion. 
Any questions regar ding toxicity  management s hould be directed to the Gilead Sciences 
Medical Monitor or designee. Please see S ection 5.3and refer to the regional prescribing 
information for details of toxicity  management with nivolumab.
7.7. Special Situations Reports
7.7.1. Definitio ns of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy  reports regardless of an 
associated AE.
Medication error is an yunintentional error in the prescribing, dispensing ,or administration 
of a medicinal product while in the control of the health care provider , subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal produ ct by 
a subject.
Misuse 
is defined as an y intentional and inappropriate useof a medicinal p roduct tha t is not 
in accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional adminis tration of a quantity  of a 
medicinal product given per administration or cumulatively  which is above the maximum 
recommended dose as per protocol or in the product labelling (as it applies to the daily  dose 
of the subject in question). In cases of a discre pancy  in drug accountability , overdose will be 
established only  when it is clear that the subject has taken the excess dose(s). Overdose 
cannot be established when the subject cannot account for the discrepancy  except in cases in 
which the investigator has reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the 
manufacture, packaging, or distribution of the medicinal product.
Andecaliximab (fo1medy GS-5745 ) 
Protoco l GS-US-296 -2013 
Gilead Sciences , Inc. 
7.7.2. 
7.7.2.1. Instruction s for Reporting Special Situations 
Instiuctions for Repo1iing Pregnancies Final 
Amendment3 
The investigator shou ld repo1i pregnancies in female study subjects that are identified after 
initiati on of study medication and throu ghout the study, including the post study drng follow-up 
period, to Gilead DSPH using the pregnancy repo1i fo1m within 24 hours of becom ing aware of 
the pregnancy. 
Refer to the eCRF completio n guidelines for full instiuct ions on the mechanism of pregnancy 
repo1iing. 
The pregnancy itself is not considered an AE, nor is an induced elective abo1iion to te1min ate a 
pregna ncy without medical reasons. 
Any premat ure te1mination of pregnancy ( eg, a spontaneo us abo1iion, an induced therapeutic 
abo1iion due to complicat ions or other medical reasons) must be repo1ied within 24 hours as an 
SAE . The underlying medical reason for this procedure shou ld be recorded as the AE te1m. 
A spontaneo us abo1iio n is always considered to be an SAE and will be repo1ied . Fmihe1more, 
any SAE occmT ing as an adverse pregna ncy outcome post study must be reported to 
Gilead DSPH . 
The subject should receive appropriate monitoring and care until the co nclusion of the 
pregnancy. The outcome shou ld be repo1ied to or Gilead DSPH using the pregnancy outcome 
repo1i fonn. If the end of the pregnancy occurs after the study has been comp leted, the ou tcome 
should be reported directly to Gilead DSPH. 
Pregnancies of female paiiners of male study subjects exposed to Gilead or other study diugs 
must also be repo1ied and releva nt info1mation sho uld be subm itted to Gilead DSPH using the 
pregnancy and pregnancy outcome fo1ms within 24 hours . Monitor ing of the s ubject should 
continue until the conclusion of the pregnancy. If the end of the pregnancy occurs after the study 
has been completed, the ou tcome should be reported directly to Gilead DSPH . 
Gilead DSPH contact infonnation is as follows: Fax: 
Email: PD 
PD 
Refer to Appendix 4 for Pregna ncy Precautio ns, D efinition for Female of Childbeai ·ing Potential , 
and Contraceptive Requirements . 
7.7.2.2. Repo1iing Other Special Situations 
All other specia l situ ation repo1is must be repo1ied on the special situat ions repo1i fonn and 
fo1wai·ded to Gilead DSPH within 24 hours of the investigator becom ing aware of the situation. 
These repo1is must consist of situations that involve study IMP and/or Gilead concomitant 
medications , but do not apply to non-Gilead concomitant medications. 
CONFIDENTIAL Page 66 16 June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 67 16June 2017Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; howev er, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form.
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to the 
eCRF completion guidelines for full instructions on the mechanism of special 
situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
Andecaliximab (fo1medy GS-5745 ) 
Protoco l GS-US-296-2013 
Gilead Sciences , Inc. 
8-
8.1. 
8.1.1. STATISTICAL CONSIDERATIONS 
Analysis Objectives and Endpoints 
Analysis Objectives 
The prima1 y object ive of this study is: Final 
Amendment3 
• To evaluate and compa re the efficacy of andecaliximab in comb ination with nivolumab 
versus nivolumab alone in subject s with recunent gastr ic adenocarcinoma 
The seco ndaiy objec tives of this study ai·e: 
• To chai·acterize and compai·e safety and tolerabi lity of andeca liximab in combination with 
nivolumab versus nivolumab alone in subject s with r ecmTent gastric adenocarc inoma 
• To chai·acterize the PK of andecalixim ab in comb ination with nivolumab 
The explorato1y objective s of this study are: 
I 
I 
I 
I 
I 
8.1.2. Primar y Endpoint 
The prima1 y endpo int of this study is ORR. ORR will be detennined from the subject s ' best 
response dming treatment. 
8.1.3. Secondary Endpoint 
The seco ndaiy endpoints of this study are: 
• Progress ion free smvival, defined as the interval from the date of rand omizati on to the earlier 
of the first documentat ion of defin itive disease progression or death from any cause . 
• Overall survival, defined as the interval from date of rand omizati on to death from any cause . 
CONFIDENTIAL Page 68 16June20 17 
Andecaliximab (fo1medy GS-5745 ) 
Protoco l GS-US-296 -2013 
Gilead Sciences , Inc. Final 
Amendment3 
• D uration ofrespo nse, defined as the interva l from the date of the first respo nse (CR or PR) is 
achieved to the earlier of the first docmnentatio n of definitive disease progressio n or death 
from any cause. 
• OccmTence of adverse events and laborato 1 y abno1ma lities during treat ment. 
8.1.4. Other Endpoint s of Intere st 
The explorato1y endpoints of this study are: 
I 
I 
8.2. 
8.2.1. 
8.2.1.1. Anal ysis Convention s 
Anal ysis Sets 
Intent-to-Treat (ITT) Analysis Set 
The I TT analysis set includes data from all randomized subjects. Study diu g assignment wi ll be 
designated acco rding to randomizat ion. 
This anal ysis set will be used in the analyses of subject characte ristics , OS, PFS, and ORR. The 
analysis of ORR base d on the ITT anal ysis set will be considered the primaiy analysis of the 
study. The analyses of D OR will be based on the su bjects in the ITT analysis set who achieve a 
CR or PR. 
Subjec ts in the ITT analysis set who do not have sufficient base line or on-study tumor status 
info1matio n to be adequately assessed for response status (ie, th ose with best overa ll responses of 
not evaluable [NE] or not detecte d [ND]) will be included in the denominators in calculatio ns of 
respo nse rates. 
8.2.1.2. Safety Analysis Set 
The Safety Analysis Set will include data from all subjects who receive 1 dose of study 
treatment , with treatme nt assignments designated acco rding to the actual treat ment received. 
This anal ysis set will be used in the analysis of safety vai·iables as well as study treatme nt 
admin istration. A ll data collected up to 30 days after the last dose of andecalix imab or 5 months 
post-treatme nt of nivolmnab, whicheve r is later, will be included in the safety sUllllllar ies. 
CONFIDENTIAL Page 69 16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 70 16June 20178.2.1.3. Pharm acod ynamic and Pharmacokinetic Anal ysis Sets
The Pharmacod ynamics and PK Anal ysis Sets will inc lude data from subjects in the Safet y 
Analysis Set who have the necessary  baseline and on- study  measurements to provide 
interpretable results for the specific parameters of interest.
8.3. Data Handling Conventions
By-subject listings will be created for important variables from each eCRF module. Summary
tables for continuous variables will contain the following statistics: N (number in population), n 
(number with dat a), mean, standard deviation, 95 % confidence intervals (CI s) on the mean,
median, minimum, and maximum. Summary  tables for categorical variables will include: N, n,
percentage, and 9 5% CIs on the percentage. Unless otherwise indicated, 95 % CI s for binary
variables will be calculated using the binomial distributi on (exact method) and will be 2 sided.
Data will be described and summarized by dose level/cohort, anal ysis set, and time point. As
appropriate, changes from baseline to each subsequent time point will be described and
summarized. Similarly , as appropriate, the best change from baseline during the study  will also
be described and sum marized. Graphical techniques (eg, waterfall plots, Kaplan -Meier [KM]
curves, line plots) may  be used when such methods are appropriate and informative.
The baseline value used in each anal ysis will be the last (most recent) pretreatment value. Data
from a ll sites will be pooled for all analy ses. Analy ses will be based upon the observed data
unless methods for handling missing data are specified. If there is a significant degree of
non-normality , anal yses may  be performed on log -transformed data or nonparam etric tests may
be applied, as appropriate.
The following censoring conventions will be applied to tumor control endpoints:
PFS: Data from surviving, non -progressing subjects will be censored at the earliest of the
time of initiation of antitumor treatment other than the study  treatment or the last time that
lack of definitive progression was objectivel y documented. Data from subjects who have
disease progression or die after ≥ 2 consecutive missing or inadequate tumor assessments 
will be censored at the la st time prior to the missing assessments that lack of definitive 
disease progression was objectively  documented.
OS: Data from surviving subjects will be censored at the last time that the subject was known
to be alive.
DOR: Data from surviving, non- progressing subjects will be censored at the earliest of the
time of initiation of antitumor treatment other than the study  treatment or the last time that
lack of definitive disease progression was objectively  documented. Data from subjects who
have d isease progression or die after ≥ 2 consecutive missing or inadequate tumor 
assessments will be censored at the last time prior to the missing assessments that lack of 
definitive disease progres sion was objectivel y documented.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 71 16June 20178.4. Demographic Data and Baseline Characteristics
Demographic summaries will include sex, race/ethnicity ,randomization stratification group , and 
age.
Baseline characteristics will include a summary  of body  weight, height, and body  mass index.
Demographic and baseline characteristics willbe su mmarized using standard descriptive 
methods
.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The null hy pothesis is that addition of andecaliximab to nivolumab will not improve ORR. The 
alternative h ypothesis is that addition of 
andecaliximab to nivolumab will improve ORR.
The Cochran -Mantel -Haenszel (CMH) Chi -square test adjusting for stratification factors will be 
performed to compare the 2 treatment groups. Subjects who do not have sufficient baseline or 
on-study  tumor assessment to charact erize response will be counted as failures. Odds ratios and 
thecorrespondi ng80% and 95% CI s will be presented.
8.5.2. Secondary Analyses
The KM method and the stratified log -rank test will be used to compare the 2 treatment groups 
for PFS and OS. A Cox proportional hazard model with the same stratification factors will be 
used to estimate the hazard ratio and corresp onding 95% CI .DOR will be analy zed using the 
KM method.
8.6. Safety Analysis
All safet y data collected on or after the date that andecaliximab /nivolumab was first 
administered up to 30 day s after thelast dose of andecaliximab or 5 months post -treatment of 
nivolumab, whichever is later, will be summarized by  treatment group ( according to the 
treatment received) . Data for the pre -treatment and post-treatment follow -up period wil l be 
included in data listings.
In general, count and percent of subjects will summarize categorical and ordinal data. 
Mean, standard deviation, minimum, quartiles, median, and maximum will summarize 
continuous data.
8.6.1. Extent of Exposure
A subject’s extent of exposure to andecaliximab and nivolumab will be generated from the study  
drug administration eCRF page. Exposure data will be summarized by  treatment group.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 72 16June 20178.6.2. Adverse Events
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA ). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT ), High -Level Term (HLT),Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summa rized on the basis of the date of onset for the event. A treatment -emergent 
AEis defined as an y AEwith onset date on or after the date of fi rst dose of study  drug up to 
30days after permanent study  drug discontinuation or an y adverse events leading to premature 
study  drug discontinuation.
Summaries (number and percentage of subjects) of treatm ent-emergent AEs (by SOC and PT) 
will be provided by  treatment group
8.6.3. Laboratory Evaluations
Selected laboratory data ( using conventional units) will be summarized using onl y observed data. 
Data and change from baseline at all scheduled time points will be summarized.
Graded laboratory  abnormalities will be defined using the CTC AE (version 4.03). Maximum 
post-baseline grade will be summarized by  count and percent of subjects with each grade.
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
1toxicity  grade from baseline at an y time post -baseline, will be summarized by  treatment group. 
If baseline data are m issing, then any  graded abnormality  (ie, at least a Grade 1) will be 
considered treatment -
emergent.
Laboratory  abnormalities that occur before the first dose of study  drug will be included in data 
listings.
8.6.4. Other Safety Evaluations
Similar general approaches to the AE and clinical laboratory data will be utilized to summarize 
other safet y measures.
8.7. Pharmacokinetic Analysis
The plasma concentrations of andecaliximab will be summarized by  nominal sampling time 
using descriptive statistics (eg, sample size, arithmetic mean, geometric mean, coefficient of 
variation (%) standard deviation, median, minimum, and maximum). Plasma concentrations of 
the study  drug over time may be plotted in semi logarithmic and linear formats as mean 
standard deviation.
Exposure -response anal ysis may  be explored as appropriate.
Andeca lixima b (fo1medy GS-5745 ) 
Protocol GS-US-296 -2013 
Gilead Sciences, Inc. Final 
Amendment3 
The numb er and pe rcentage of positive or negative anti-andecaliximab antibody values at each 
specified time-point will be summ arized. The effect of anti-andeca liximab a ntibody on 
andecalix imab PK, safety, and efficacy may be evaluated. 
8.8. Biomarker Anal ysis 
Descr iptive statistics of baseline and chan e in biom arkers will be 
time for all sub· ects b tr eatment aims. 
8.9. Interim Safety Anal ysis 
After approxi mately 20 subjects ai·e treate d for 12 weeks, a D MC will review safety data on 
these subjects and r ecommend to Gilead wh ether the treatment has demonstrated acceptab le 
tolerability. Thereafter , review of safety data will be peifonned at regulai· intervals as descr ibed 
in the DMC chaiier. 
8.10. Sample Size 
Assumin g the ORR for subj ects ti·eated with n ivolumab alone is 25% , 120 subjects in total are 
needed to detect an im prove ment of20% in ORR for subjects treate d with andecalix imab and 
nivolumab with appro ximately 83% power at one-sided signi ficance level of 10% using a CMH 
test. The assum ption of nivolumab ORR is based on the upper bound of the 95% CI of the 
estimated ORR in CheckMa te-032 Study {Le 2016 }. 
8.11. Data Monitoring Committee 
In addition to th e review of the interim safety analysis after approx imately 20 subjects are ti·eated 
12 weeks , a D MC will review the prog ress of the s tudy and perfo1m interim reviews of safety 
data at inte1vals as described in the D MC chaiier and provide recommendatio ns to Gilead 
whether t he nature , frequency, and severity of adverse effects associate d with study ti·eatment 
wairn nt the eai·ly te1minatio n of the study in the best interests of the paiiic ipants, whether the 
study should continue as planned, or the study shou ld continue with m odificatio ns. The DMC 
may also provide recommendatio ns as needed regai·ding study design. 
The DMC's specific activities will be defined by a mutually agreed chaiier , which will define the 
DMC 's mem bership, conduct, and m eeting schedule. 
While the DMC will be asked to advise Gilead regarding future conduct of the study, inclu ding 
possib le eai·ly study tennination, Gilead retains final decisio n-ma king authority on all aspects of 
the study. 
CONFIDENTIAL Page 73 16June20 17 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 74 16June 20179. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the b asic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigat or’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following completion of the study. Study completion is defined as the date when the 
last sub
ject completes the protocol -defined activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC any modifications made to the protocol or any accompa nying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
Theinvestigator is responsible for obtaining written informed consent from eac h individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 75 16June 2017Theinvestigator must use the most current IRB/IEC approved consen t form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by IRB/ IEClocal 
requirements. The consent form will inform subjects about genomic testing and sample retention, 
and their right to receive clinically  relevant genomic anal ysis results .
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed b y local l aw) and an identification code will be recorded on any  
form or biological sample submitted to the Sponsor, IRB/IEC ,or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to spe cific laboratory  instructions.
NOTE: Theinvestigator must keep a screening log showing codes, names, and addresses for all 
subjects screened and for all subjects enrolled in the trial. Subject data will be processed in 
accordance w ith all applicable regul ations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the study  drug, and an y other study information, 
remain the sole and exclusive propert y of Gilead during the conduct of the study  and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigato r further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate an d accurate records to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following 2 categories: (1)investigator’s study file, and (2) subject 
clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, I RB/IEC and governmental 
approval with correspondence, informed consent, drug records, staff curriculum vitae and 
authorization forms, and other appropriate docu ments and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject :
Subject identification (name, date of birth, gender)
Documentation that subject meets eligibility  criteria, i e, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria)
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 76 16June 2017Documentation of the reason(s) a consented subject is not enrolled
Participation in study  (including study  number)
Study  discussed and date of inf ormed consent
Dates of all visits
Documentation that protocol specific procedures were performed
Results 
of efficacy  parameters, as required b y the protocol
Start and end date (including dose regimen) of study  drug , including dates of dispensing and 
return
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity )
Concomitant medication (including start and end date, dose if relevant; dose changes)
Date of study  completion and reason for earl y discont inuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe , or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified by  regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for t he continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function is documented according to study  procedures. TheeCRF should 
be completed on the day  of the subject visit to enable the sponsor to perform central monitoring 
of safet y data.  The Eligibility  Criteria eCRF should be completed onl y after all data related to 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 77 16June 2017eligibility  have been received.  Subsequent to data entry , a study  monitor will perform source 
data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or a ny interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff, 
who rout inely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entry, and pro viding the reason 
for the update ( eg,data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a read -only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5 .
9.1.7. Study Drug Accountability and Return
Gilead recommends that used and unused study  drug supplies be returned to the shipping facility  
from which it came for eventual destruction. The study  monitor will provide instructions for 
return. If return is not possible, the study  monitor will evaluate each stud y center’s study  drug 
disposal procedure s and provide appropriate instruction for destruction of unused study  drug
supplies. I f the site has an appropriate standard operating procedure (SOP) for drug destruction
as determined b y Gilead , the site may  destroy  used (empty or partiall y empty ) and un
used study  
drug supplies in accordance with th atsite’s approved SOP. A copy  of the site’s approved SOP 
will be obtained for central files. 
If study  drug is destro yed on site, the investigator must maintain accurate records for all study  
drug destroy ed. R ecords must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug . Upon study  completion, 
copies of the study  drug accountability  records must be filed at the site. Another cop y will be 
returned to Gilead .
The study  monitor will review study  drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud ymonitors , toIRB/IEC, or to regulatory  authorit y or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 78 16June 20179.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to the IRB/IEC in 
accordance with local requirements and receive documented IRB/ IECapproval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agency (ies). Gilead 
will ens ure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed b
y or with the consent 
of Gilead in an abstract, manuscript, or present ation form or the stud y has been completed at 
all study  sites for at least 2 y ears.
The investigator will submit to Gilead any  proposed publication or presentation along with 
the respective scientific journal or presentation forum at least 30 day s before submission of 
the publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4 ).
The investigator will comply  with Gilead’s request to delete references to its confidenti al 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg, attendance at I nvestigator's Meetings.  If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 79 16June 20179.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
eCRF .
The monitor is responsib le for routine review o f the eCRF at regular intervals throughout the 
study  to verify  adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the eCRF . The investigator agrees to cooperate with the monitor to ensure 
that any  problems detected through an y type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authoriti es or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 80 16June 201710. REFERENCES
Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, et al. Dy strogl ycan 
is selectively  cleaved at the parenchy mal basement membrane at sites of 
leukocy te extravasation in experimental autoimmune encephalom yelitis. J Exp 
Med 2006;203 (4):1007 -19.
Antonia SJ, Bendell JC, Tay lor MH, Calvo E, Jaeger D, De Braud FG, et al. Phase I /II stud y of 
nivolumab with or without ipilimumab for treatment of recurrent small c ell lung 
cancer (SCL C): CA209 -032 [Abstract 7503]. J Clin Oncol (ASCO Annual 
Meeting Abstracts) 2015.
Ardi VC, Van den Steen PE, Opdenakker G, Schweighofer B, Dery ugina EI , Quigley  JP. 
Neutrophil MMP- 9 proenzy me, unencumbered by  TIMP-1, undergoes efficient
activation in vivo and cataly tically  induces angiogenesis via a basic fibroblast 
growth factor (FGF -2)/FGFR -2 pathway . J Biol Chem 2009;284 (38):25854 -66.
Castaneda FE, Walia B, Vijay -Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted 
deletion of m etalloproteinase 9 attenuates experimental colitis in mice: central 
role of epithelial -derived MMP. Gastroenterology  2005;129 (6):1991-2008.
Chau I , Norman AR, Cunningham D, Oates J, Hawkins R, I veson T, et al. The impact of primary  
tumour origins in patie nts with advanced oesophageal, oesophago- gastric junction 
and gastric adenocarcinoma --individual patient data from 1775 patients in four 
randomised controlled trials. Ann Oncol 2009;20 (5):885-91.
Chen EI , Kridel SJ, Howard EW, L i W, Godzik A, Smith JW. A unique substrate recognition 
profile for matrix metalloproteinase -2. J Biol Chem 2002;277 (6):4485 -91.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and 
metastasis. Cell 2006;124 (2):263-6.
Dery ugina EI, Quigle y JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: 
contrasting, overlapping and compensatory  functions. Biochim Biophy s Acta 
2010;1803 (1):103 -
20.
Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, et al. Resis tance of 
young gelatinase B -deficient mice to experimental autoimmune encephalomy elitis 
and necrotizing tail lesions. J Clin Invest 1999;104 (11):1507 -15.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur 
J Cancer 2009;45 (2):228 -47.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 81 16June 2017Farina AR, Mackay  AR. Gelatinase B/MMP -9 in Tumour Pathogenesis and Progression. Cancers 
2014;6 (1):240 -96.
Ferlay  J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 
v1.0, Cancer Incidence and Mortality  Worldwide: IARC CancerBase No. 11. 
Available at http://globocan.iarc.fr. Accessed 09 July  2014. International Agency  
for Research on Cancer  2013.
Fife BT, Pauken KE. The role of the PD -1 pathway  in autoimmunity  and peripheral tolerance. 
Ann N Y Acad Sci 2011;1217:45-59.
Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor 
microenvironment. Nature immunology  2013;14 (10):1014
-22.
Garg P, Vijay -Kumar M, Wan g L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix 
metalloproteinase -9-mediated tissue injury  overrides the protective effect of 
matrix metalloproteinase -2 during colitis. American journal of ph ysiology . 
Gastrointestinal and liver phy siology  2009;296 (2):G175-84.
Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized 
comparison between chemotherap y plus best supportive care with best supportive 
care in advanced gastric cancer. Ann Oncol 1997;8 (2):163 -8.
Heissig B, Hattori K, Dias S , Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and 
progenitor cells from the bone marrow niche requires MMP -9 mediated release of 
kit-ligand. Cell 2002;109 (5):625 -37.
Hijova E. Matrix metalloproteinases: their biological functions and cli nical implications. 
Bratislavske lekarske listy  2005;106 (3):127 -32.
Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as 
therap y for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6 
(6):480-98.
Imai K, Yokohama Y, Nakanishi I, Ohuchi E, Fujii Y, Nakai N, et al. Matrix metalloproteinase 7 
(matrily sin) from human rectal carcinoma cells. Activation of the precursor, 
interaction with other matrix metalloproteinases and enzy mic properties. J Biol 
Chem 1995;270 (12):6691-7.
Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix 
metalloproteinase -2 and matrix metalloproteinase -9 in antibody -induced arthritis. 
J Immunol 2002;169 (5):2643-7.
Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental 
metastasis is suppressed in MMP-9- deficient mice. Clinical & experimental 
metastasis 1999;17 (2):177 -
81.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 82 16June 2017Kang JH, L ee SI, L im do H, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherap y for 
pretreated gastric cancer : a randomized phase III trial comparing chemotherapy  
plus best supportive care with best supportive care alone. J Clin Oncol 2012;30 
(13):1513-8.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD- 1 and its ligands in tolerance and immunity . 
Annu Rev Immunol 20 08;26:677 -704.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor 
microenvironment. Cell 2010;141 (1):52 -67.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Mi yagawa N, et al. CD4(+)CD25high 
regulatory  T cells increase wi th tumor stage in patients with gastric and 
esophageal cancers. Cancer immunology , immunotherapy  : CII 2006;55 (9):1064 -
71.
Kridel SJ, Chen E, Kotra L P, Howard EW, Mobashery  S, Smith JW. Substrate hy drolysis by  
matrix metalloproteinase -9. J Biol Chem 2001; 276 (23):20572-8.
Lausch E, Keppler R, Hilbert K, Cormier -Daire V, Nikkel S, Nishimura G, et al. Mutations in 
MMP9 and MMP13 determine the mode of inheritance and the clinical spectrum 
of metaph yseal anad ysplasia. American journal of human genetics 2009;85
(2):168-78.
Le DT, Bendell JC, Calvo E, Kim JW, Ascierto PA, Sharma P, et al. Safety and activity  of 
nivolumab monotherapy  in advanced and metastatic (A/M) gastric or 
gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 
study  [Abstrac t 06]. J Clin Oncol (ASCO Annual Meeting Abstracts) 2016.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD -1 Blockade in 
Tumors with Mismatch- Repair Deficiency . N Engl J Med 2015;372 (26):2509 -20.
Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A. Matrix metalloproteinase -9 inhibition 
ameliorates pathogenesis and improves skeletal muscle regeneration in muscular 
dystrophy . Human molecular genetics 2009;18 (14):2584 -98.
Lu B, Chen L, Liu L, Zhu Y, Wu C, Jiang J, et al. T- cell-mediated tumor immune surveillance 
and expression of B7 co -inhibitory  molecules in cancers of the upper 
gastrointestinal tract. Immunologic research 2011;50 (2- 3):269-75.
Miyazaki D, Nakamura A, Fukushima K, Yoshida K, Takeda S, Ikeda S. Matrix 
metalloproteinase -2ablation in dy strophin-deficient mdx muscles reduces 
angiogenesis resulting in impaired growth of regenerated muscle fibers. Human 
molecular genetics 2011;20 (9):1787 -99.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 83 16June 2017Mott JD, Werb Z. Regulation of matrix biology  by matrix metalloproteinases. Current opinion in 
cell biology  2004;16 (5):558-64.
Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therap y 
with 5 -fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. 
Cancer 1993;72 (1):37 -41.
Muro K, Bang Y, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. A Phase 1B Study  of 
Pembrolizumab (Pembro; MK -3475) in Patients (PTS) with Advanced Gastric 
Cancer [Abstract LBA15]. Ann Oncol 2014.
Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory  bow el disease. 
Molecular aspects of medicine 2005;26 (4 -5):379 -90.
Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al. Clinical significance of 
programmed death -1 ligand -1 and programmed death- 1 ligand -2 expression in 
human esophageal cancer. Cli n Cancer Res 2005;11 (8):2947 -
53.
Oken MM, Creech RH, Tormey  DC, Horton J, Davis TE, McFadden ET, et al. Toxicity  and 
response criteria of the Eastern Cooperative Oncology  Group. Am J Clin Oncol 
1982;5 (6):649 -55.
Olson MW, Gervasi DC, Mobashery  S, Fridman R. Kinetic anal ysis of the binding of human 
matrix metalloproteinase -2 and - 9 to tissue inhibitor of metalloproteinase (TI MP)-
1 and TIMP -2. J Biol Chem 1997;272 (47):29975 -83.
Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeti ng of 
gelatinase B and chemokines in multiple sclerosis. L ancet neurology  2003;2 
(12):747-56.
Perng DW, Chang KT, Su KC, Wu YC, Chen CS, Hsu WH, et al. Matrix metalloprotease-9 
induces transforming growth factor -beta(1) production in airway  epithelium via 
activation of epidermal growth factor receptors. Life Sci 2011;89 (5 -6):204
-12.
Power DG, Kelsen DP, Shah MA. Advanced gastric cancer --slow but steady  progress. Cancer 
treatment reviews 2010;36 (5):384 -92.
Pyrhonen S, Kuitunen T, Ny andoto P, Kouri M. Rando mised comparison of fluorouracil, 
epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive 
care alone in patients with non -resectable gastric cancer. Br J Cancer 1995;71 
(3):587-91.
Santana A, Medina C, Paz- Cabrera MC, Diaz -Gonzalez F, Farre E, Salas A, et al. Attenuation of 
dextran sodium sulphate induced colitis in matrix metalloproteinase -9 deficient 
mice. World J Gastroenterol 2006;12 (40):6464- 72.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 84 16June 2017Scheithauer W, Komek G, Zeh B, Stoger FX, Schenk T, Henja M, et al. Palliative Chemoth erapy 
vs. Supportive Care in Patients With Metastatic Gastric Cancer: A Randomized 
Trial [Abstract 68]. Conference on Biology , Prevention and Treatment of 
Gastrointestinal Malignancies; 1995 09- 12 January ; Koln, Germany . 
Shih JY, Yuan A, Chen JW, Yang PC. Tumor -Associated Macrophage: I ts Role in Cancer 
Invasion and Metastasis. Cancer Mol. 2006;2 (3):101-6.
Swaika A, Hammond WA, Joseph RW. Current state of anti -PD-L1 and anti -PD-1 agents in 
cancer therap y. Mol Immunol 2015;67 (2 Pt A):4 -17.
Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of sy stemic 
second -line therapy . J Clin Oncol 2011;29 (35):4709 -14.
Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan 
versus best supportive care (BSC) as second -line therap y in gastric cancer: A 
randomized phase III study  of the Arbeitsgemeinschaft Internistische Onkologie 
(AIO) [Abstract 4540]. J Clin Oncol (ASCO Annual Meeting Abstracts) 2009.
Topalian SL , Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, 
durable tumor remission, and long- term safet y in patients with advanced 
melanoma receiving nivolumab. J Clin Oncol 2014;32 (10):1020-30.
Van Wart HE, Birkedal- Hansen H. The cy steine switch: a principle of regulation of 
metal loproteinase activity  with potential applicability  to the entire matrix 
metalloproteinase gene family . Proc Natl Acad Sci U S A 1990;87 (14):5578 -82.
Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 
activation and inhi bition. J Biol Chem 2007;282 (52):37585-96.
Vu TH, Shipley  JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP -9/gelatinase B is 
a key  regulator of growth plate angiogenesis and apoptosis of hy pertrophic 
chondrocy tes. Cell 1998;93 (3):411-22.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey  A, Fleig WE. Chemotherapy  in advanced 
gastric cancer: a s ystematic review and meta -analy sis based on aggregate data. J 
Clin Oncol 2006;24 (18):2903-9.
Wesolowski R, Lee C, Kim R. I s there a role for second- line c hemotherapy in advanced gastric 
cancer? Lancet Oncol 2009;10 (9):903-12.
Wolchok JD, Hoos A, O'Day  S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the 
evaluation of immune therap y activity  in solid tumors: immune -
related response 
criteria. Clin Cancer Res 2009;15 (23):7412 -20.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 85 16June 201711. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. ECOG Performance Status
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 5. Revised RECIST Guideline (version 1.1)
Andecaliximab (formerly GS-5745) 
Protocol GS-US-296-2013 
Gilead Sciences, Inc. 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT Final 
Amendment 3 
A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 
Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or 
Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma 
GS-US-296-2013, Amendment 3, 16 June 2017 
This protocol has been approved by Gilead Sciences, Inc. The foJlowing signature documents 
this approval. 
PD 
PPD (Printed) PPD 
Gilead Sciences Medical Monitor 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol , including all appendices, and I agree that it contai ns all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide aJl study personnel under my supervision copies of the protocol and access to all 
infon nation provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Princ ipal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDENTIAL Page 86 16 June 2017 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 87 16June 2017Appendix 2. Study Procedures Table
Period
Screening
Randomizationa
Treatm ent
EOTm
Disease 
Progression
EOSn
30 day Safety 
Follow-upo
5-month Safety 
Follow-Upp
Long Term 
Follow-Up
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 to 50
Week -4 Day 1 2 4 6 8 10 12 14 16 18 20 22 24 to 96
Window (day) -28 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7
Informed Consent X
Medical and 
Medication History X
Physical 
Examinationb X X X X X X X XsX X X
Vital Signs & 
WeightX X X X X X X X X X X X X X X X X
ECOG Performance 
Statusc X XcX X X X X XsX X X
12-lead ECG X X X X X X X XsX X
Adverse events/
Concomitant 
MedicationsdX X X X X X X X X X X X X X X X X X X
IWRS Registration X X X X X X X X X X X X X X X X
Study Drug/
Nivolumab 
AdministrationeX X X X X X X X X X X X X
Hem atology X X X X X X X X X X X X X X X X X X
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 88 16June 2017Period
Screening
Randomizationa
Treatm ent
EOTm
Disease 
Progression
EOSn
30 day Safety 
Follow-upo
5-month Safety 
Follow-Upp
Long Term 
Follow-Up
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 to 50
Week -4 Day 1 2 4 6 8 10 12 14 16 18 20 22 24 to 96
Window (day) -28 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7
Chemistry X X X X X X X X X X X X X X X X X X
Thyroid Function 
Tests (TSH, T3, free 
T4)X X X XtX X X X
Coagulation X X X
Urinalysis X X X X X X X XsX X X X
Pregnancy TestfX X X X X X X XsX X X X
Andecaliximab PKgX X X X XrX X
Anti-Andecaliximab
Antibodyh X X X X XrX X
Blood B iomarkersiX X X X X X XrXiXi
Oral S ampling X
CT or MRI & 
Treatment Response 
Asse ssmentkX X X XtXqX
CCI
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 89 16June 2017Period
Screening
Randomizationa
Treatm ent
EOTm
Disease 
Progression
EOSn
30 day Safety 
Follow-upo
5-month Safety 
Follow-Upp
Long Term 
Follow-Up
Visit 1 2 3 4 5 6 7 8 9 10 11 12 13 14 to 50
Week -4 Day 1 2 4 6 8 10 12 14 16 18 20 22 24 to 96
Window (day) -28 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±7 ±7 ±7
Tumor BiopsylXl Xl
(Wk 5 through W k 9)Xl
Overall Survival and 
Other Antitumor 
TherapyXu
a Day 1 visit must occur within 3 days following randomization.
b Complete physical examination (PE) to be performed at Screening, EOT and EOS. A modified PE capturing changes from prior exams will be performed at subsequent visits . 
Height is required at Screening only.
c ECOG performance status on Day 1 may be waived if has been conducted during screening within 4 days of Day 1 . 
d Adverse events will be asses sed and concomitant medications will be recorded at each clinic visit from Screening up to and inc luding the 30 -day Safety Follow -up visit or 
EOS visit whichever is later.  
e For Arm A: Study drug andecaliximab (800 mg) will be administered via IV infusion every 2 weeks over 30 (± 5) min. Nivolumab (3 mg/kg) will b e administered via IV 
infusion following the completion of andecaliximab every 2 weeks over 60 (± 5) min. For Arm B: Nivolumab alone (3 mg/kg) will beadministered via IV infusion every 
2weeks over 60(± 5) min.
f If applicable (females of child bearing potential). Serum pregnancy testing will be conducted at Screening. Urine pregnancy t esting will be conducted pre -dose on Day 1and 
then every 4 weeks ,at EOT, and EOS, 30-day, and 5 -month Safety Follow -up.
g For Arm A only, plasma samples will be collected for andecaliximab PK at 30(± 15) min after the end of infusion on Day 1 .  For Weeks 4, 8, 16, and 24 and every 3 months
thereafter, PK will be collec ted prior to dosing and 30(± 15) min after the end of infusion.  It will also be collected at EOT and EOS.      
h For Arm A only,  serum samples for anti-andecaliximab antibody will be collected prior to dosing on Day 1 , Week 4, Week 8 , Week 16, Week 24, and every 3 months 
thereafter, EOT and EOS.
i Blood biomarkers will be collected at screening and prior to dosing on Day 1 ; Week 2 ; Week 4 ; Week 8 ; Week 16 ; Week 24 and every 3 months thereafter and at progression 
or EOS .
k Tumor evaluation by CT or MRI will be performed during screening and approximate ly every 8 weeks regardless of visit week
or dose interruption. Scan at EOS visit is not 
necessary if restaging scan is performed within the prior 8 weeks. Treatment response assessment will be per RECIST v1.1.
For subjects who stop study treatment in the absence of disease progression (eg. experienced unexpected toxicity) and remain on stud y for follow up for progression -free 
survival , tumor evaluation by CT or MRI should continue approximately every 8 weeks until disease progression or initiation of non -study specific anti-neoplastic therapy in 
the absence of progression, whichever occurs earlier.
CCII 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 90 16June 2017l A pretreatment biopsy is requested if archival tumor sample provided to meet Inclusion Criterion #6 is from before the last line of therapy . An on -treatment biopsy is required 
between Week 5and Week 9. A biopsy at disease progression is requested , if medically feasible .The sample should be collected by the last clinic visit on study ie EOS or 
30Day Safety Follow up visit. All biopsies are requeste d to be from gastric lesions if possible (non -gastric metastatic lesions ok if no gastric lesions possible). See laboratory 
manual for biopsy specifications and procedures.
m End of treatment (EOT) assessments will be completed only by subjects who discont inue all treatment for reasons other than progressive disease , initiation of new anti-
neoplastic treatment
,or full withdrawal of consent .  These assessments should be completed as soon as possible after the decision is made. Every attempt should be made t o 
keep the subject in the study and continue to perform tumor evaluation by CT or MRI approximately every 8 weeks until disease progression.
n End of study (EOS) assess ments will be completed when a subject meets at least 1 of the criteria for study discontinuation (Section 3.7).
o The 30 -day safety follow up visit will be performed following the last dose of andecaliximab .  
p The 5 -month safety follow up visit will be performed following the last dose of nivolumab. 
q If imaging shows progressive di sease (PD), it is at the discretion of the investigator to keep the subject on study treatment or to stop study treatment unt il imaging is repeated 
≥4 weeks later in order to confirm PD (see section 6.2.9 ).
r Starting at Week 24, p erform every 12 weeks unt il EOT/ EOS .
s Starting at Week 24, p erform every 4 weeks until EOT/ EOS .
t Starting at Week 24, perform every 8 weeks until EOT/ EOS .
u Perform every 3 months until 5 years.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 91 16June 2017Appendix 3. ECOG Performance Status
Grade
0 Fully active, able to carry on all pre -disease performance without restriction
1Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house w ork, office w ork
2Ambulatory and capable of all self-care but unable to carry out any work activities.
Up and about more than 50% of w aking hours
3 Capable of only limited self-care, confined to bed or chair more than 50% of w aking hours
4 Com pletely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5 Dead
Reference for ECOG {Oken 1982 }
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 92 16June 2017Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Pregnan cy and Contraception Requirements for Males and Females of Childbearing 
Potential
The risks of treatment with 
andecaliximab during pregnancy  have not been evaluated in humans. 
Thepotential for genotoxicity is not expected given that andecaliximab is a monoclonal 
antibody . In both the rat and rabbit definitive embr yo-fetal developmental to xicitystudies, there 
were no andecaliximab- related effects on embr yo-fetal survival and growth and no fetal 
anomalies. Ina fertility studyin male and female ra ts, no test articl e-related effects on 
reproductive performance and intrauterine survival were observed at a ny dosage level. A 
clinically  relevant interaction between andecaliximab and contraceptive steroids is not expected 
because of their distinct metabolic pathway s and therefore, hormonal contraception may  be used 
as part of the birth control methods.
Please refer to the latest version of the investigator’s brochure for additional information.
Please refer to the regional prescribing information for inf ormation on the potential risks of 
treatment with nivolumab. 
2)Definition of Female of Childbearing Potential
For the purposes of this study , a
female subject of childbearing potential is a woman who has not 
had a h ysterectom y, bilateral oophorectom y, or medicall y documented ovarian failure. This 
definition includes pubertal females regardless of whether or not she has had a menses 
(premenarchal, Tanner Stage 3) and perimenopausal women who have had a spontaneous 
menses in the last 12 months. A woman who has had a tubal sterilization is considered to be of 
childbearing potential.
Women ≤ 54years of age with amenorrhea of an y duration will be cons idered to be of 
childbearing potential unless they  have had a hy sterectom y, bilateral oophorectom y, or 
medically  documented ovarian failure .
Women > 54 years of age with cessation (for ≥12 months) of previously  occurring menses 
due to ovarian failure will not be considered to be of childbearing potential.
3)Contraceptive Requirements for Females
Female subjects of childbearing potential must agree to use protocol specified highl y effective 
method(s) of contraception from the screening/ randomization visit through out the study  period, 
90days following the last dose of 
study  drug andecaliximab and 5 months after the last dose of 
nivolumab unless the subject chooses continuous heterosexual abstinence as a lifesty le choice . 
The investigator should counsel subjects on the protocol specified method(s) for avoiding 
pregnancy  during the study . See the listed below for the protocol specified contraceptive 
methods. 
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 93 16June 2017Female stud y subjects who are not heterosexually active must have periodic confirmation of 
continued absti nence from heterosexual intercourse and regular pregnancy testing while taking 
study  drug .The investigator should counsel subjects on the protocol specified method(s) for 
avoiding pregnancy  in case the subject chooses to engage in heterosexual intercourse.
Female subjects of childbearing potential must have a negative serum pregnancy  test at s creening 
and a negative urine pregnancy  test every  4 weeks starting on Day 1,prior to receiving the dose 
of study  drug. Lactating females must discontinue nursing before 
study  drug administration.
Protocol specified contraceptive methods:
Complete abstinence from intercou rse. Periodic abstinence (eg , calendar, ovulation,
symptothermal, post- ovulation methods) is not permitted.
Or
Consistent and correct use of 1 of the following methods of birth control listed below, 
inaddition to a male partner who correctly  uses a condom from the date of Screening until
90days after last dose of study  drug andecaliximab and 5 months a fter the la st dose of 
nivolumab:
intrauterine device (IUD) with a failure rate of < 1% per year
female barrier method: cervical cap or diaphragm with spermicidal agent
tubal sterilization
vasectomy in male partner
implants of levonorgestrel
injectable progesterone
oral contraceptives (either combined or progesterone only )
contraceptive vaginal ring
transdermal contraceptive patch
Female subjects must agree to refrain from egg donation or egg harvesting for the purpose of 
fertilization during the course of the stud y for at least 90 days after the last dose of 
andecaliximab and 5 months after the last dose of nivolumab.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 94 16June 20174)Contraceptive Requirements for Males
Male subjects must agree to use condoms and avoid sperm donation from the 
screening/ randomization visit throughout the study  period ,and for at least 90days after 
administration of the last dose of study  drug andecaliximab or nivolumab
.
5) Procedures to be Followed in the Event of Pregnancy
Subjects should be instructed to notify  the investigator if they (or their partne r)become pregnant 
at an y time during the study, or if they become pregnant within 90days following the last dose 
of andecaliximab and within 5 months after the last dose of nivolumab .Subjects who become 
pregnant or who suspect that they  are pregnant dur ing the stud y must report the information to 
the investigator and discontinue study  drug immediately . The investigator should report all 
pregnancies to the CRO Safety  Department using the pregnancy  report form within 24 hours of 
becoming aware of the pregn ancy . The investigator should counsel the subject regarding the 
possible effects of prior study  drug exposure on the fetus and the need to inform the study  site of 
the outcome of the pregnancy . Subjects whose partner has become pregnant or suspects she is 
pregnant during the study  must report the information to the investigator. Instr uctions for 
reporting partner pregnancy , pregnancy  and pregnancy  outcome are outlined in Section 7.7.2.1 .
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 95 16June 2017Appendix 5. Revised RECIST Guideline (version 1.1)
Please see reference (E.A. Eisenhower, et al. New response evaluation criteria in solid tumours: 
Revised RECI ST guideline (version 1.1) European Journal of Cancer 45(2009) 228
-247.) for full 
RECI ST guidelines.
Measurable Lesions :
Tumor ≥10 mm in longest diameter (LD) on an axial image on CT or MRI with ≤5mm 
reconstruction interval If slice thickness >5 mm, LD must be at least 2 times the thickness
Tumor ≥20 mm L D by chest x -ray (if clearl y defined & surrounded b y aerated lung); CT is 
preferre d (even without contrast)
Tumor ≥10 mm L D on clinical evaluation (photo) with electronic calipers; skin photos 
should include ruler Lesions which cannot be accurately measured with calipers should be
recorded as non- measurable
Lym ph nodes ≥15 mm in short a xis on CT (CT slice thickness no more than 5 mm)
Ultrasound cannot be used to measure lesions
Note: only  patients with measureable disease at baseline should be enrolled onto the study .
Non-Measurable Lesions :
All other definite tumor lesions
Masses <10 mm
Lym ph nodes 10 -14 mm in short axis
Leptomeningeal disease
Ascites, pleural or pericardial effusion
Inflammatory  breast disease
Lym phangitic involvement of skin or lung
Abdominal masses or organomegal y identified b y physical exam which cannot be 
measured b y reproducible imaging techniques
Benign findings are NEVER included. Also, do not include equivocal (“cannot exclude”) 
findings
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 96 16June 2017Target Lesions :
Choose up to 5 lesions (up to two (2) per organ)
Add up longest diameters (LD) of non -nodal lesions (axial plan e)
Add short axis diameters of nodes
This is the “sum of the longest diameters” (SL D)
Time point response: patients with target (+/ -non target) disease
Target lesions Non-Target lesions New lesions Overall response
CR CR No CR
CR Non-CR/non -PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo SD
SDNon-PD or not all 
evaluatedNo NE
Not all evaluated Non-PD No PD
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = Progressive disease, and NE = inevaluable.
Time point response: patients with non -target disease only
Non-target lesions New lesions Overall response
CR No CR
Non-CR/non -PD No Non-CR/Non -PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = Progressive disease, and NE = inevaluable.
a “Non -CR/non -PD’ is preferred over “stable disease’ for non -target disease since SD is increasingly used as endpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
Andecaliximab (formerly GS -5745)
Protocol GS -US-296-2013 Final
Gilead Sciences, Inc. Amendment 3
CONFIDENTIAL Page 97 16June 2017Overall response
First time pointOverall response
Subsequent time point BEST overall response
CR
CRCR
PRCR
SD, PD or PRa
CR SD SD provided minimum criteria for  SD duration met, otherwise, PD
CR PD SD provided minimum criteria for  SD duration met, otherwise, PD
CR NE SD provided minimum criteria for  SD duration met, otherwise NE
PR CR PR
PR PR PR
PR SD SD
PR PD SD provided minimum criteria for  SD duration met, otherwise, PD
PR NE SD provided minimum criteria for  SD duration met, otherwise NE
NE NE NE
CR= com plete respons e,PR=partial response, SD=stabledisease, PD=progre ssivedisea se,and
NE=inevalu able.
a If a CR is truly  met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria 
relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best  response would 
depend on  whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed when subsequent scans 
suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these 
circumstances, the original CR should be changed to PR and the best response is PR.
http://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf. New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1) E.A. Eisenhauer ,*, P. Therasseb, J. Bogaertsc, L.H. Schwartzd, D. Sargente, R. Fordf, J. 
Danceyg, S. Arbuckh, S. Gwytheri, M. Mooneyg, L. Rubinsteing, L. Shankarg, L. Doddg, R. Kaplanj, D. Lacombec, J. Verweijk